Cardiovascular disease in rheumatoid arthritis by Pahau, Helen
  
  
  
Cardiovascular Disease in Rheumatoid Arthritis  
Helen Louise Ruiha Pahau  
Diploma (RcompN), PgDip (HSM)  
  
  
  
  
A thesis submitted for the degree of Doctor of Philosophy at  
The University of Queensland in 2015  
The University of Queensland, Diamantina Institute  
 i  
  
Abstract   
This thesis focuses on cardiovascular (CV) disease (CVD) risk in 
rheumatoid arthritis (RA). Inflammation and CV risk factors are increased 
in RA patients. This population has a higher carotid intima-media thickness 
and more CV events than the general population and kynurenine (KYN) 
concentration levels are higher in RA patients compared to healthy controls. 
Therefore, in this thesis inflammation and CVD risk factors are investigated 
for increased risk of future RA development. RA and type2 diabetes (T2D) 
carotid intima-media thickness (CIMT) are compared and measurements of 
serum KYN for CVD, cancer and mortality are studied. First I tested the 
hypothesis that inflammation, CVD and CV risk factors are associated with 
increased risk of future RA development. Data from the Norwegian HUNT 
population health survey were obtained to compare groups with RA at 
baseline and follow-up (HUNT2 and HUNT3, n = 429) or follow up alone 
(HUNT3, n = 786), or without RA at both times (n = 33,567). Results 
showed female gender, age, smoking, body mass index (BMI), and history 
of previous CVD were associated with self-reported incident RA (previous 
CVD: odds ratio 1.52 (95% confidence interval 1.11-2.07). The findings 
regarding previous CVD were confirmed in sensitivity analyses excluding 
participants with psoriasis (odds ratio (OR) 1.70 (1.232.36)) or restricting 
the analysis to cases with hospital diagnosis of RA (OR 1.90 (1.10-3.27)) or 
carriers of the shared epitope (OR 1.76 (1.134-2.74)). History of previous 
CVD was not associated with increased risk of osteoarthritis (OR 1.04 
(0.86-1.27)). I then compared the characteristics of CV risk and progression 
of CIMT in 78 RA patients from an outpatient Rheumatology Clinic and 
212 patients with T2D who attended a community or hospital diabetes clinic 
in Brisbane. We found that the burden of risk varied between the 2 cohorts. 
RA patients were older, had a higher proportion of smokers, females and 
previous CVD. T2D patients had a higher body mass index (BMI), diastolic 
blood pressure, triglycerides, lower high density lipoprotein and a higher 
statin use. At baseline, CIMT measurements were similar in the RA and 
T2D cohorts.  In an adjusted linear regression model, RA was significantly 
associated with lower CIMT at follow-up. Despite a shorter follow-up, 91 % 
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of the T2D cohort had increased CIMT at follow-up compared to 54 % of 
the RA cohort. In the RA cohort, disease modifying anti-rheumatic drug 
(DMARD) use at baseline was associated with significantly lower CIMT 
values at follow-up.   
Finally we hypothesized that increased KYN in RA patients may predispose 
to CVD, infections and cancer. We measured KYN in 129 RA patients 
followed for 10 years for development of CVD, cancer and death. Median 
KYN concentrations were significantly higher in RA patients than in 
controls, but there was large overlap between groups. There were no 
variables in our data set that could explain the differences in KYN 
concentrations among the RA patients and KYN concentrations did not 
predict development of CVD, new malignancies or death. The number of 
pack-years of smoking was the only variable associated with death in 
logistic or Cox regression analysis. In summary, CVD risk factors are 
associated with increased risk of future RA development. The burden of risk 
varies in RA and T2D, and CIMT progression is slower for RA than for 
T2D. Although serum KYN concentrations are significantly higher in RA 
than in controls, they were not associated with CVD, new malignancies or 
death.  
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Chapter 1: Literature Review   
Rheumatoid Arthritis  
 
1.1  Introduction   
Rheumatoid Arthritis (RA) is a common systemic inflammatory disorder 
primarily involving the joints.  This arthritis is progressive and if 
inadequately treated, significant functional disability can occur within 10 
years [1]. The pattern of disease activity varies in patients, and often 
includes periods of high disease activity interspersed with periods of low 
disease activity. The precise aetiology of RA is unknown, however a 
combination of environmental and genetic factors are implicated [2]. There 
is a reduced median life expectancy of 7-10 years for people with RA and 
premature cardiovascular disease (CVD) is primarily responsible [3]. 
Despite treatment advances, RA patients continue to have significantly 
higher mortality and morbidity rates than the general population [4].   
At present there is no cure for RA. Current goals of treatment include (1) 
early and intensive management; (2) suppression of disease activity; (3) 
limitation of disease progression and (4) adequate treatment of co-
morbidities. Continued research and subsequent advances in therapeutics 
have recently enhanced effective treatment of this disease.  
 
1.2  Epidemiology  
The annual incidence of RA is reported to be approximately 0.03 percent 
[5]. Although RA can affect any age group the peak age of onset is between 
30 and 55 years [6]. Women are affected two to three times more often than 
men [7]. There is currently an overall decline in the incidence of RA and 
this is more evident in the female population [8]. The disease prevalence is 
approximately 1 percent in Caucasians, but varies between ethnicities 
including 0.1 percent (in rural Africans) and 56 percent (in Pima and 
Chippewa Indians) [5].   
 
1.3  Aetiology  
The exact cause of RA is unknown however a number of factors are 
implicated in the aetiology. Current evidence suggests that both genetic and 
environmental factors are involved.  
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1.3.1 Genetic Factors  
Increasing evidence suggests RA is highly heritable.  There is greater 
disease concordance in monozygotic twins (12-15%) than dizygotic twins 
(3.5%) [9, 10].   Recent population health studies have also shown that 
prevalence of RA is higher in first degree relatives of people with RA [11, 
12]. These twin and first-degree relative studies suggest genetic factors have 
a significant impact on susceptibility to RA. Estimated genetic contribution 
to RA is thought to be as high as 50% to 60% [13, 14].  
The best-established genetic association is with the human leukocyte 
antigen (HLA) locus, in particular the HLA-DR B1 chains known as the 
shared epitope (SE) [15]. The SE are known to be associated with RA 
susceptibility [16], specifically susceptibility to Anti-citrullinated protein 
antibody (ACPA) positive RA [17].    
 
The presence of anti-citrullinated protein antibody (ACPA) measured by 
anti-cyclic citrullinated antibodies (anti-CCP) is highly specific for RA [18, 
19] and are reported to be a good predictor for the development of RA [20].   
In addition to the major histocompatibility complex (MHC) alleles (HLA in 
humans), there are non MHC alleles that are associated with RA risk and 
also other autoimmune diseases [21]. For instance PAD 14 is associated 
only with RA, whilst PTPN22 is linked to RA, systemic lupus 
erythematosus, type 1 diabetes and other auto immune diseases [22-24]. 
 
1.3.2 Environmental factors  
Smoking is the most established and studied environmental risk factor for 
RA [25, 26]. There is a strong association with smoking and sera-positive 
RA, [27, 28] with established interactions between the HLA-DR shared 
epitope (SE) in ACPA positive RA patients [29]. This gene environment 
interaction does appear to differ between ethnic groups. A cross-sectional 
study involving African Americans with early RA, did not find an 
association between smoking and ACPA-positive RA patients [30]. 
Furthermore RA cases in an Asian cohort demonstrated that the 
combination of SE alleles and smoking was associated with risk of RA, 
however ACPA status was not [31].   
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The association between HLA SE and smoking appears to hold irrespective 
of the number of cigarettes smoked. A recent study showed that there is a 
40% higher risk among ever smokers compared to never smokers [32], 
indicating that light or heavy exposure increases risk of developing RA, 
likely due to activation of the immune system against citrullinated protein 
antigens [33].   
 
1.4  Pathogenesis   
Alteration in immune function leads to joint inflammation, degradation and 
destruction in RA. CD4+ T cells are regarded as the protagonists in 
initiating the inflammatory response in RA [34]. Numerous cytokines are 
expressed in synovial tissue and an imbalance between pro and anti-
inflammatory cytokines induces chronic inflammation [35]. The inflamed 
synovium contains various macrophage and fibroblast derived cytokines 
that further support the activation of CD4+ Tcells. Tumor necrosis factor 
(TNF-α) and interleukin-1 (IL-1β), are considered key pro-inflammatory 
cytokines in the pathogenesis of RA [36, 37]. In vitro studies suggest that 
IL-1β cause cartilage destruction by stimulating the release of matrix 
metalloproteinases and other degradative products increases bone 
reabsorption by stimulating osteoclast differentiation and activation [38]. 
Damage to articular cartilage in RA begins at the cartilage pannus interface, 
with progressive erosions occurring into subchondral bone [38].    
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Figure 1-1: In the healthy joint (a) the thin synovial membrane lines the non-weight-
bearing aspects of the joint. In rheumatoid arthritis (b) the synovial membrane 
becomes hyperplastic and infiltrated by chronic inflammatory cells. Ultimately it 
develops into 'pannus', which migrates onto and into the articular cartilage and 
underlying bone.  
    
1.5  Clinical Features  
The symptoms of RA predominantly consist of pain, swelling and stiffness 
of the joints. RA typically begins insidiously, with the signs and symptoms 
developing slowly over weeks to months. However in a third of the patients, 
onset is rapid and can occur over days or weeks [39].  
 
The metacarpophalangeal (MCP), proximal interphalangeal (PIP), 
metatarsalphalangeal joints (MTP) and the wrist are the most common joints 
affected. In some patients the shoulders, elbows, knees and ankles may also 
be affected. If this disease is left untreated, deformity of the joint and 
disability can occur within 10 years of onset of disease [40]. However 
achieving remission is within reach, and the earlier that RA treatment is 
started the better the odds are of reaching remission.   
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RA patients with extra articular manifestations have increased morbidity 
and mortality [41] and extra articular manifestations appear to be most 
common in patients with severe disease activity [42]. Severe weight loss, 
osteoporosis and CVD are examples of extra articular manifestations [43].  
 
Table 1-1: Criteria for inclusion as extra-articular manifestations of RA 
Criteria for inclusion as extra-articular manifestations of RA 
1. Pericarditis (A) Clinical judgment and exudation verified by echocardiography 
 If ultrasound not available: criteria according to Hara et al4 
 (B) Clinical criteria: (1 required) 
 
Typical pericardial pain, peripheral oedema, 
dyspnoea/orthopnoea, ascites, dysrythmia (heart rate >140/min, 
atrial flutter/fibrillation, 2–3 degree atrioventricular block, 
ventricular tachycardia) 
 Objective criteria compatible with pericarditis: (1 required) 
 Physical examination 
 Cardiac catheterisation findings 
 Histological examination 
 
Other causes improbable, such as tuberculosis or other infection, 
metastases, primary tumour, postoperative status or other trauma 
2. Pleuritis Clinical judgment and exudation verified by x ray examination 
 
Other causes improbable, such as tuberculosis or other infection, 
metastases, primary tumour, postoperative status or other trauma 
3. Felty’s syndrome 
Splenomegaly (clinically evident or measured by ultrasound) and 
neutropenia (<1.8×109/l) on two occasions 
 Other causes improbable, such as drug side effect or infection 
4. Major cutaneous 
vasculitis Diagnostic biopsy or clinical judgment by dermatologist 
5. Neuropathy 
Clinical judgment by doctor and signs of 
polyneuropathy/mononeuropathy at 
electromyography/electroneurography 
 Other causes, such as diabetes or alcohol abuse, improbable 
6. Scleritis, episcleritis or 
retinal vasculitis Clinical judgment by ophthalmologist 
7. Glomerulonephritis Clinical judgment by nephrologist and positive biopsy 
8. Vasculitis affecting 
other organs 
Clinical judgment by organ specialist and biopsy compatible with 
vasculitis 
9. Amyloidosis Clinical judgment and positive biopsy from affected organ 
10. Keratoconjunctivitis 
sicca Clinical judgment 
 
Positive rose-bengal staining or result of Schirmer’s test <5 
mm/min 
11. Xerostomia Clinical judgment 
 
Abnormal sialometry, sialography, salivary scintigraphy or 
salivary gland biopsy with lymphocytic infiltrate 
12. Secondary Sjögren’s 
syndrome Two of three criteria: 
 Keratoconjunctivitis sicca (see above) 
 Xerostomia (see above) 
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Serological evidence: rheumatoid factor, ANA, anti-Ro (SSA), 
anti-La (SSB) positive, or hypergammaglobulinaemia 
13. Pulmonary fibrosis Clinical judgment and 
 
Decreased vital capacity or carbon dioxide transfer factor by 15% 
from normal 
14. Bronchiolitis 
obliterans organising 
pneumonia Clinical judgment by pulmonologist 
15. Cervical myelopathy Clinical judgment 
 Increased atlantoaxial movement—verified by x ray examination 
16. Subcutaneous 
rheumatoid nodules Clinical judgment 
17. Rheumatoid nodules 
in other locations Positive biopsy 
 
Downloaded from http://ard.bmj.com/ on December 17, 2014 - Published by 
group.bmj.com 
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1.5.1 Classification Criteria  
The 1987 American College of Rheumatology (ACR) criteria were used to 
classify patients with RA until 2010 (Table 2). For the diagnosis of RA, 
patients must fulfil 4 out of 7 criteria including morning stiffness 1 hour, 
arthritis of 3 joint areas, arthritis of hand/wrist joints, symmetrical arthritis, 
rheumatic nodules, serum rheumatoid factor (RF) and radiographic changes 
[44]. The criteria distinguished patients with   established RA from other 
arthritides and identified patients with moderate to severe disease.   
 
Table 1-2: The 1987 revised criteria for the classification of RA by the ACR  
Criterion   Description  
1. Morning Stiffness  Morning  stiffness  in 
 and around the joints, 
lasting at least one hour before 
maximal improvement  
2. Arthritis of 3 or more joint 
areas  
At least three joint areas (out 
of 14 possible; right or left 
PIP, MCP, wrist, elbow, 
ankle, MTP joints) 
simultaneously have had soft 
tissue swelling or fluid (not 
bony overgrowth) as observed 
by a physician  
3. Arthritis of hand 
joints  
At least one area swollen (as 
defined in criterion two) in a 
wrist, MCP, or PIP joint  
4. Symmetric arthritis  Simultaneous involvement (as 
in criterion two) of the same 
joint areas on both sides of the 
body (bilateral involvement of 
PIP, MCP, or MTP joints 
without absolute symmetry is 
acceptable)  
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5. Rheumatoid nodules  
Subcutaneous nodules over 
bony prominences or extensor  
 surfaces, or in juxta-articular 
regions as observed by a 
physician  
6. Serum rheumatoid 
factor  
Demonstration of abnormal 
amounts of serum rheumatoid 
factor by any method for 
which the result has been 
positive in <5% of normal 
control subjects  
7. Radiographic changes  Radiographic changes typical 
of rheumatoid arthritis on 
posteroanterior hand and wrist 
radiographs, which must 
include erosions or 
unequivocal body 
decalcification localized in, or 
most marked adjacent to, the 
involved joints (osteoarthritis 
changes alone do not qualify)  
  
In 2010 the American College of Rheumatology (ACR) and the European 
League Against Rheumatism (EULAR) revised the classification criteria to 
allow capture of RA patients with early and milder disease, while still 
allowing application to patients with established and more severe disease 
(Table 3) [45].    
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Table 1-3: The 2010 American College of Rheumatology / European League Against Rheumatism classification criteria for 
rheumatoid arthritis  
  Score  
Target population (Who should be tested?): Patients who  
1) have at least 1 joint with definite clinical synovitis (swelling)  
2) with the synovitis not better explained by another disease  
Classification criteria for RA (score-based algorithm: add score of categories 
A–D;  
a score of ≥6/10 is needed for classification of a patient as having definite 
RA                
A. Joint involvement  
1 large joint  
2-10 large joints   
1-3 small joints (with or without involvement of large joints)  
4-10 small joints (with or without involvement of large joints)  
>10 joints (at least 1 small joint)  
B. Serology (at least 1 test result is needed for classification)  
Negative RF and negative ACPA  
Low-positive RF or low-positive ACPA   
High-positive RF or high-positive ACPA   
C. Acute-phase reactants (at least 1 test result is needed for classification)  
Normal CRP and normal ESR 
 
Abnormal CRP or normal ESR   
 
 
D. Duration of symptoms 
 
                            <6 weeks  
  
                            ≥6 weeks   
 
 
 
 
 
   
 
  
  
  
  
  
  
  
0  
1 
2 
3  
5  
 
0 
2  
 3 
 
0 
1 
 
                            0 
1  
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1.5.2 Diagnosis and disease activity  
The diagnosis of RA is made via a thorough assessment of patient 
symptoms, physical examination and additional investigations in accordance 
with the classification criteria.  
 
1.6 Rheumatoid Factor  
Rheumatoid factor (RF) is a complex of antibodies directed against the 
conserved end of immunoglobulin (IgG) antibodies.  It occurs in 60% of 
patients at diagnosis and rises to approximately 80% with time.  It is 
associated with more severe disease and a greater risk of atherosclerosis. 
The specificity for RF is however relatively low (60-70%) and is also 
detected in patients with other diseases and also in the healthy population.   
 
1.6.1 Anti- citrullinated protein antibodies   
ACPA are auto-antibodies directed against peptides and proteins that are 
citrullinated.  ACPA are used as a clinical biomarker for the diagnosis of 
RA, and have a 55-80% sensitivity and specificity of 90-98% for RA [46, 
47].  The presence of ACPA is also a prognostic marker and is associated 
with more aggressive disease [48], preceding the clinical manifestations of 
RA by up to 10 years along with RF [19, 49]. Furthermore, there is evidence 
of significant interactions between the HLADRB1 shared epitope and 
cigarette smoking in the development of ACPA-positive RA [50, 51]. Sero-
positive RA is more common (70%) than sero-negative disease (30%) and is 
associated with more aggressive disease and extra- articular manifestations 
[52].    
 
1.6.2 CRP and ESR   
C - reactive protein (CRP) is a member of the pentraxin family, a pattern-
recognition protein and a host-defence-related component of the innate 
immune system [53-55]. CRP was discovered in 1929 and is the most 
characteristic acute phase protein in the human body [56]. CRP is a sensitive 
marker of systemic inflammation, and the plasma concentration levels are 
elevated in RA patients and in other conditions with both acute and chronic 
inflammation [56-58]. Although CRP is a non-specific test, doctors may 
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utilise the test to assist the effectiveness of a specific arthritis treatment and 
to monitor periods of disease flare-up.  
 
Erythrocyte sedimentation rate (ESR) measures how fast red blood cells fall 
through a column of blood. It is an indirect index of acute-phase protein 
concentrations (particularly fibrinogen) and is a sensitive but non-specific 
test used to assist in the detection of inflammation associated with auto 
immune diseases, infections and cancers [59]. Similar to CRP, doctors may 
utilise ESR to test the effectiveness of specific arthritis treatment and to 
follow inflammation levels.  
 
1.7 Disease Activity Scores   
In order to evaluate the need for, and the effect of treatment in patients with 
RA, it is valuable to measure the disease activity at diagnosis and follow-up 
in a standardized manner. For this purpose several scores have been 
developed. The Disease Activity Score (DAS) was developed in Europe as a 
continuous activity score [60].  This score takes into account the patient’s 
general health, the number of swollen and tender joints as well as the ESR: a 
non-specific measure of inflammation. The DAS28 takes into account 28 
different joints.  A value >5.1 is regarded as high disease activity, <3.2 is 
regarded as low activity and <2.6 is regarded as remission. Figure 2 by 
comparing a patient’s DAS28 score over multiple time points, one can 
substantiate his/her improvement or response. The EULAR response criteria 
are shown in Figure 3.  
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Figure 1-2: Disease activity score 28  
 From: DAS-Score.nl. Available at http://www.das-score.nl/www.das-
score.nl/index.html               
    
Table 1-4: DAS 28   
PRESENT DAS28  DAS28 IMPROVEMENT OVER TIME POINTS  
  >1.2  0.6-1.2  <0.6  
<3.2  Good response  Moderate response  No response  
3.2-5.1  Moderate response  Moderate response  No response  
>5.1  Moderate response  No response  No response  
 
DAS Score  
DAS28  >5.1  
 
=  high  disease  activity  
DAS28  <3.2  
DAS28 <2.6 = remission   
=  low  disease  activity  
 
Treatment response over time is also a crucial component of patient 
assessment, although largely a tool for clinical trial ACR score measures % 
treatment response, i.e., ACR20 requires at least a 20 percent improvement 
in both the number of swollen and tender joints, as well as a 20 percent 
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improvement in three of the following five parameters: ESR, health 
assessment questionnaire (HAQ), physician’s global assessment of disease 
activity, patient’s global assessment and patient’s pain [61]. 
Correspondingly, the ACR50 requires a 50% improvement and the ACR70 
a 70% improvement. Furthermore, the ACR has defined remission criteria 
based on the same variables [62].   
 
1.8  Imaging  
Radiography remains the mainstay of imaging in the diagnosis and follow-
up of RA. RA patients should have a hand and wrist x-ray, and baseline x-
rays of affected joints to document any future erosive changes. Erosions 
often develop in the first year but may occur at any time. A previous study 
showed radiographically demonstrable erosions were present in 30% of their 
patients at diagnosis, and in 70% 3 years later [63].  The use of newer 
imaging modalities such as ultrasonography, magnetic resonance imaging 
(MRI) and computerized tomography (CT) are increasingly being used to 
assist in the diagnosis and continuing management of RA [64]. Many of the 
imaging methods offer greater sensitivity in detecting synovitis, effusions, 
joint subluxations, joint space narrowing and bone edema then standard x-
ray [65]. Furthermore, when compared with conventional methods, the 
increasing use of ultrasound has allowed for a greater success rate when 
aspirating joints, and greater accuracy when injecting steroids into affected 
joints [65].  
 
1.9  Treatment  
RA rarely spontaneously remits.  As the exact pathophysiology is unknown 
and there is currently no cure, treatment aims to suppress and modulate the 
inflammatory disease. Supportive ancillary treatments such as 
physiotherapy, occupational therapy, podiatry and surgery are used as 
adjuncts.  Medications used in RA aim to suppress the ‘overactive’ immune 
system.  Different drugs with various mechanisms of action are utilised and 
often a combination of therapies is needed.    
 
Non-steroidal anti-inflammatory agents (NSAIDs) have analgesic and anti-
inflammatory effects. They are used effectively to assist with RA 
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symptoms. They also have significant gastric and cardiac toxicity [66]. The 
gastrointestinal toxicity appears to be related to cyclooxygenase 1 (COX) 
inhibition. However COX-2 inhibitors with an improved gastrotoxicity 
profile have been found to increase the risk of atherothrombosis even with 
short-term use.   
 
Current medications used to treat RA span the history of medicine, from 
intramuscular gold to targeted cytokine blocking agents.  The exact 
mechanism of action of the many of the disease modifying agents 
(DMARDs) is incompletely understood.  Disease modifying (or slow 
acting) antirheumatic drugs include Methotrexate (MTX), Sulphasalazine 
(SSZ), Leflunomide, Hydroxchloroquine (HCQ), Gold, Cyclosporine, 
Azathioprine and Corticosteroids.  Biologic (B)DMARDs are newer 
therapeutics and they interfere with the immune system in a more selective 
way, targeting cytokines or signalling pathways.  However, both DMARDs 
and B-DMARDs suppress immune and inflammatory pathways and hence 
RA activity.   
 
Methotrexate is the most frequently used DMARD in RA and the 
foundation therapeutic for DMARD and biologic combinations [67]. Results 
of multiple double-blind, randomised studies have indicated that MTX 
improves the health of patients (e.g. improving health assessment 
questionnaire scores and those of other quality of life measures), and 
decreases systemic inflammation (e.g. erythrocyte sedimentation rate, 
concentrations of CRP and signs of clinical inflammation [68, 69].  
Patients react differently to anti-rheumatic medications and often require 
varying doses or combinations to manage their disease. Adverse effects are 
not uncommon. The medications used to treat RA mostly take several 
months or longer to achieve remission.  However over the last decade, the 
development of new and effective treatments and treatment regimens has 
substantially improved the prognosis for patients with RA. Many patients 
now experience lower disease activity and remission than in the 1970s and 
1980s [70].  
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1.10 Early arthritis clinics and ‘treat to target’ regimens    
1.10.1 Early arthritis clinics  
There is substantial evidence that early treatment with DMARDs can lead to 
better outcomes, including the suppression of synovitis, prevention of bone 
destruction, and the reduction of functional disability and mortality rates. 
The late 80s saw the introduction of the concept of ‘early intervention’ [71]. 
Soon after, specialised early arthritis clinics (EAC) [72] were created in 
multiple centres around the world, ensuring early diagnosis and treatment. 
The EAC most often represents a structured environment where patients can 
be assessed, reviewed and treated in a protocol-driven manner, utilising 
best-practice therapeutics and technology.  
 
1.10.2 Treat to target regimens  
In 2008, an international expert panel primarily of Rheumatologists 
reviewed available goal directed therapy in RA, resulting in the 
International Treat to Target initiative [73]. The panel introduced 
overarching principles (Figure 3) and 10 recommendations for “Treat 
Arthritis to Target” (Figure 4).  There are extended guidelines from both 
European and American Rheumatology expert groups which, although 
generally similar, vary in the type of medications used. The aim of the treat-
to-target therapeutic approach is to bring RA under control quickly and to 
prevent joint damage and disease progression.   
  
Overarching principles:  
a. The treatment of rheumatoid arthritis must be based on a shared decision between patient and rheumatologist.  
b. The primary goal of treating the patient with rheumatoid arthritis is to maximize long-term, health-related 
quality of life through control of symptoms, prevention of structural damage, normalization of function and social 
participation.  
c. Abrogation of inflammation is the most important way to achieve these goals.  
d. Treatment to target by measuring disease activity and adjusting therapy accordingly optimizes outcomes in 
rheumatoid arthritis.  
Figure 1-3: Recommendations  
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1. The primary target for treatment of rheumatoid arthritis should be a state of clinical remission. 
2. Clinical remission is defined as the absence of signs and symptoms of significant inflammatory disease 
activity.   
3. While remission should be a clear target, based on available evidence low disease activity may be an 
acceptable alternative therapeutic goal, particularly in established long-standing disease.  
4. Until the desired treatment target is reached, drug therapy should be adjusted at least every 3 months.  
5. Measures of disease activity must be obtained and documented regularly, as frequently as monthly for patients 
with high/moderate disease activity or less frequently (such as every 3–6 months) for patients in sustained low 
disease activity or remission.  
6. The use of validated composite measures of disease activity, which include joint assessments, is needed in 
routine clinical practice to guide treatment decisions.  
7. Structural changes and functional impairment should be considered when making clinical decisions, in 
addition to assessing composite measures of disease activity.  
8. The desired treatment target should be maintained throughout the remaining course of the disease.  
9. The choice of the (composite) measure of disease activity and the level of the target value may be influenced 
by consideration of co-morbidities, patient factors, and drug-related risks.  
10. The patient has to be appropriately informed about the treatment target and the strategy planned to reach this 
target under the supervision of the rheumatologist  
Figure 1-4: Ten recommendations on treating rheumatoid arthritis to target based on both evidence and 
expert opinion: From: Ann Dis Rheum. 2010, 69:631-637 [73]  
    
An algorithm was proposed for treating RA to target (Fig 4) and is based on the recommendation in 
Fig 3.  
  
Figure 1-5: Algorithm for treating RA to target. Indicated as separate threads are the main 
target (remission and sustained remission) and the alternative target (low disease activity in 
patients with long-term disease), but the approaches to attain the targets and sustain them are 
essentially identical. Adaptation of therapy should usually be done by performing control 
examinations with appropriate frequency and using composite disease activity measures which 
comprise joint counts  
From: Ann Rheum Dis. 2010;69:631-637 [73]  
 
1.11 Mortality and Morbidity in RA  
Patients with RA have increased mortality and morbidity when compared to 
healthy controls [74, 75].  The increased mortality predominantly relates to 
increased cardiovascular disease [76-79].  It was found in a retrospective 
study of an inception cohort of RA patients that they were at increased risk 
of cardiovascular death, ischemic heart disease and heart failure compared 
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to age and sex matched community controls. The incidence of 
cardiovascular events was significantly higher among those with RA 
compared with controls (3.43 versus 0.59 per 100 patient-years) [80].  
Another study of 3501 patients with RA with follow-up for 35 years, found 
that mortality was increased twofold, resulting in a decreased lifespan of 7 
to 10 years [81]. Mortality directly due to RA itself was low (9.8 percent of 
the deaths). Other studies suggest that increased inflammation associated 
with RA appears to contribute substantially to increased cardiovascular 
mortality [82].    
 
1.12 Cardiovascular Disease   
CVD is the result of damage and dysfunction within the vascular tree.  This 
damage occurs as a result of loss of vessel compliance, damage to 
components of vessel walls leading to plaques, evolution of aneurysms and 
exposure of thrombotic wall components with resultant clot formation.   
This damage causes the vascular tree to fail in different ways, leading to 
particular clinical states.  
 
1.12.1 Epidemiology  
CVD is common in the general population, affecting the majority of adults 
over the age of 60 years. The prevalence of coronary heart disease (CHD) is 
approximately 1/3 to 1/2 that of total CVD. The lifetime risk of CHD was 
illustrated in a study of 7733 participants, age 40 to 94, in the Framingham 
Heart Study who were initially free of CHD [83].  The lifetime risk for 
individuals at age 40 was 49% in men and 32% in women. Even those who 
were free from disease at age 70 had a lifetime risk of 35% in men and 24% 
in women [83]. While young patients in a large autopsy study had fatty 
streaks [84], not all adults develop clinically apparent CVD as fatty streaks 
progress at different rates in different individuals [85].    
 
1.13 Atherosclerosis  
Generalised thickening of the arteries with subsequent loss of wall 
compliance is known as arteriosclerosis.  Atherosclerotic heart disease, 
otherwise known as coronary heart disease or coronary artery disease, is 
most often caused by atherosclerosis that occurs due to the deposition of 
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cholesterol in the arterial wall causing plaque accumulation. Resulting 
chronic inflammation in the plaques can lead to the thinning and rupture of 
the endothelial cap and exposure of thrombogenic core.  This then leads to 
the formation of a platelet thrombosis often leading to vessel occlusion and 
tissue infarction [86]. The presence of atherosclerosis is associated with 
arteriosclerosis.  
 
The vascular endothelium was previously considered to be an inert barrier 
between the blood and tissues, however increasing evidence suggests that 
the endothelium is an active biological interface.  The single layer of 
continuous endothelium lining arteries and veins forms a unique 
thromboresistant layer between blood and potentially thrombogenic 
subendothelial tissues [87, 88].    
 
The exact pathogenesis of endothelial damage is not known, however a 
range of risk factors has been shown to be associated with accelerated 
vascular damage.  These include environmental and genetic factors such as 
smoking, hypertension, obesity, ageing, lack of exercise, inflammation, 
diabetes and family history. Intima media thickness (IMT) increase begins 
with endothelial dysfunction and is generally considered the earliest sign of 
atherosclerosis.   
 
The activity of endothelial cells includes regulation of vascular tone and 
structure. This is accomplished by releasing molecules such as nitric oxide 
and prostacyclin, which control vasodilatation and vasoconstriction [89]. 
Endothelial cells also provide both a non-thrombotic and non-adherent 
arterial surface for leukocytes [88]. Endothelial dysfunction therefore is 
defined as impaired vasodilatation or vasoconstriction to stimuli, pro-
inflammatory surface state, and prothrombotic surface state [90].  
The changes usually occur slowly over time and vary greatly from 
individual to individual.  The first observable change of atherosclerosis is 
the formation of a fatty streak.  In one autopsy study in the US, for example, 
all 2876 men and women, aged 15 to 34 years, had aortic fatty streaks [91].  
The fatty streak is caused by an excess deposition of lipid in macrophages in 
the vessel wall.  With time these cells swell, there is deposition of 
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extracellular lipid and the plaque grows.  Fibrous tissue is deposited, areas 
calcify and the plaque increases in size.  The increasing plaque size can 
encroach on the vessel lumen, reducing blood flow and causing ischaemia 
of downstream tissue, and causing symptoms such as angina.  With time, the 
fibrous cap thins, and with exposure to the shear stress of the turbulent 
blood flow, is at risk of rupture.  Upon rupture, the thrombogenic contents 
rapidly cause clotting leading to vessel occlusion.  This occlusion can lead 
to tissue death, such as a myocardial infarction (MI) [92].   
 
Concurrent with the plaque formation there is generalised vascular damage 
where the lining of the vessel thickens.  There is good correlation between 
generalised arteriosclerosis, focal atherosclerosis and risk of CVD [93].  
This arteriosclerosis causes a loss of vessel wall compliance, which 
increases the load on the vessel and the heart.  In healthy vascular trees this 
is a reflection of the normal systolic outflow.  The wave of ejected blood 
from the heart is partially reflected back from the peripheral arteries.  
Normally this is reflected back in diastole and does not load the heart.  
However as the vessels lose compliance and stiffen this wave is reflected 
back earlier and eventually arrives in systole.  This reflected wave adds 
additional load to the heart and the extra workload accelerates the 
progression of heart disease [94].  Decreased aortic compliance has been 
shown to be predictive of primary coronary events in hypertensive patients 
with normal renal function [95].  
 
1.13.1 Risk Factors for atherosclerosis  
There are many risk factors for atherosclerosis.  These factors show 
individual variation and no single factor acts in isolation. The worldwide 
INTERHEART study of patients from 52 countries, identified nine 
potentially modifiable factors accounting for over 90 percent of the 
population with an attributable risk of a first MI [96].  These included 
smoking, dyslipidaemia, hypertension, diabetes, abdominal obesity, 
psychosocial factors, regular alcohol consumption, not consuming a daily 
intake of fruits and vegetables, and not regularly participating in physical 
activity.  Non modifiable risk factors include male sex, age, and a family 
history of CVD.   
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1.13.2 CRP and atherosclerosis  
The association of elevated CRP concentrations and increased risk of CVD 
is well documented [97]. CRP levels are elevated in response to 
inflammatory stimuli; therefore it is thought that CRP may play a direct role 
in the development of atherosclerosis in inflammatory disease such as RA 
[98, 99].  
 
1.14 Effects of Dyslipidaemia in CVD  
Lipid abnormalities play a critical role in the development of 
atherosclerosis. Lipids such as cholesterol and triglycerides are insoluble in 
plasma. Circulating lipid is carried in lipoproteins that transport the lipid to 
various tissues for energy utilisation, lipid deposition, steroid hormone 
production, and bile acid formation [100]. Lipoprotein consists of esterified 
and unesterified cholesterol, triglycerides, and phospholipids and protein 
[100]. The protein components of the lipoprotein are known as 
apolipoproteins.  The different apolipoproteins serve as cofactors for 
enzymes and ligands for receptors. There are five major lipoproteins, each 
of which has a different function.  In clinical practice measurement of the 
low density lipoprotein (LDL), high density lipoprotein (HDL) and total 
cholesterol level are the most relevant [101].      
 
Animal studies have demonstrated accelerated atherosclerosis with a high 
cholesterol diet [102]. In humans, worldwide epidemiologic studies show an 
increasing incidence of atherosclerosis when serum cholesterol 
concentrations are > 3.9 mmol/L.  The different lipoproteins have particular 
effects on vessel health.  In the clinical context high levels of LDL and low 
levels of HDL are particularly important risk factors for CVD [103].     
LDL cholesterol can promote inflammatory and immune changes via 
cytokine release from macrophages and antibody production.  Circulating 
LDL rapidly accumulates in the cholesterol enriched macrophages (foam 
cells), but not directly in the lipid core of atherosclerotic plaque [104].  
Oxidative modification of LDL is necessary for macrophage uptake via 
unregulated scavenger receptors and accelerated accumulation of cholesterol 
[105].  Macrophage uptake of LDL cholesterol may initially be an adaptive 
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response, which prevents LDL-induced endothelial injury [106].  
Cholesterol accumulation in foam cells leads to mitochondrial dysfunction, 
apoptosis, and necrosis with resultant release of cellular proteases, 
inflammatory cytokines, and prothrombotic molecules [106].   
Oxidized LDL can cause disruption of the endothelial cell surface [107], 
promote inflammatory and immune changes via cytokine release from 
macrophages and antibody production, and increase platelet aggregation.  It 
may also play a role in plaque instability.  Levels of oxidized LDL are 
increased in patients with an acute coronary syndrome and are positively 
correlated with the severity of the syndrome [108].  Low HDL levels are 
more common in patients with a first myocardial infarction than in age-
matched controls without CHD (19 versus 4 percent) [109].  
HDL, in contrast to LDL, has antiatherogenic properties that include reverse 
cholesterol transport, maintenance of endothelial function, protection 
against thrombosis, and maintenance of low blood viscosity through a 
permissive action on red cell deformability [110].  The net effect is that 
there is an inverse relationship between plasma HDL-cholesterol levels and 
cardiovascular risk. Values above 1.9 mmol/L are associated with a 
longevity syndrome [111]. 
   
Much of the anti-atherogenic effect of HDL is thought to be mediated by 
reverse cholesterol transport, a process whereby excess cholesterol in cells 
and in atherosclerotic plaques is removed [112].  Initially hepatic and 
intestinal cells synthesise small nascent HDL particles composed of 
phospholipids and apolipoproteins [113]. These HDL particles gather 
surface components (phospholipids, cholesterol, and apolipoproteins) from 
triglyceride-depleted chylomicron and very low density lipoprotein (VLDL) 
remnants [113]. They also acquire free (unesterified) cholesterol from tissue 
sites and other lipoproteins, as the initial HDL particles contain relatively 
little cholesterol. Apo A-I on the surface of HDL plays a central role in this 
process. It serves as a signal transduction protein to mobilize cholesterol 
esters from intracellular pools [113].   
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1.14.1 Lipid modification and CVD risk  
There is extensive evidence that modification of dyslipidaemia can lower 
the risk of CVD.  This evidence is both for primary (patients without 
evidence of CVD) and secondary (patients with CVD) prevention.  There 
are multiple studies which assess the relationship between dyslipidaemia 
and CVD.  A meta-analysis of 38 primary and secondary prevention trials 
found that for every 10 percent reduction in serum cholesterol, coronary 
heart disease mortality was reduced by 15 percent and total mortality risk by 
11 percent. No increase in non-coronary heart disease mortality was seen 
[114, 115].  
 
Lipid modification is achieved by medications, predominantly by HMG-
CoA reductase inhibitors also known as statins.  They lower cholesterol by 
inhibiting the enzyme HMG-CoA reductase, which is the rate-limiting 
enzyme of the mevalonate pathway of cholesterol synthesis [116]. Inhibition 
of this enzyme in the liver stimulates LDL receptors, resulting in an 
increased clearance of LDL from the bloodstream and a decrease in blood 
cholesterol levels. The first results can be seen after one week of use and the 
effect is maximal after four to six weeks [116]. However the mechanisms by 
which lipid-lowering therapy (particularly with statins) is beneficial, are 
incompletely explained by the serum LDL concentration at baseline or after 
treatment [117].  Although statins probably cause regression of 
atherosclerosis, an improvement in outcome can be demonstrated as early as 
six months: a time considered too early for significant plaque regression 
[118].  Among the non-lipid mechanisms that may be involved in CVD 
reduction are plaque stabilization, reduced inflammation, reversal of 
endothelial dysfunction, and decreased thrombogenicity [119].  
One important effect of statin therapy may be maintenance of integrity of 
the fibrous cap of the plaque, thereby protecting against plaque rupture. This 
effect appears to be mediated by inhibition of macrophage proliferation, 
reduced expression of matrix metalloproteinases (MMPs) and tissue factor 
(which promotes thrombus formation) by macrophages, and an increase in 
tissue inhibitor of metalloproteinase-1 [120]. Statin therapy, given as 
primary or secondary prevention, reduces the serum CRP concentration, an 
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effect that is mostly unrelated to lipid levels at baseline or during therapy 
[121]. The fall in serum CRP begins within 14 days of treatment [122].  
Additional evidence that statins may have an anti-inflammatory effect is 
provided by a randomized trial that found that patients with rheumatoid 
arthritis experienced modest clinical improvement in their RA with 
atorvastatin.  Atorvastatin also reduced CRP levels and the ESR compared 
with placebo [123]. In clinical trials, statins appear to have greater effects in 
patients with evidence of inflammation at baseline. The potential 
importance of statin-induced reduction in serum markers of inflammation 
was illustrated by an analysis from the secondary prevention cholesterol and 
recurrent event (CARE) trial [124]. Patients with baseline serum 
concentrations of CRP and serum amyloid A in the highest quintile had a 
relative risk for a recurrent event 75 percent higher than those with levels in 
the lowest quintile.   
 
How statins might interfere with the inflammatory response is not well 
understood. One possible mechanism is impairment of inflammatory cell 
adhesion by inhibition of the main beta-2 integrin, LFA-1[125, 126].  Other 
contributing factors may include reduced lipidation of intracellular proteins 
and reduced expression of major histocompatibility complex class II 
molecules on antigen presenting cells in response to interferon, decreasing 
subsequent T-lymphocyte activation [127].  
 
1.15 Assessment of CVD in RA  
It is hard to power interventional studies in RA to look at definitive CVD 
endpoints.  This is because it is difficult to obtain a large enough cohort of 
patients to show a treatment difference in mortality or cardiovascular events.  
Therefore a surrogate measure of a person’s risk for future CVD is ideal.  In 
recent years, the evolution of non-invasive ultrasound techniques has 
allowed assessment of cardiovascular health.  These techniques can detect 
vascular dysfunction, and appear to correlate well with future risk of CVD.  
An ideal situation to assess a person’s risk for CVD would be to know the 
exact state of their vascular tree.  Currently there is no such technique.  All 
current tests are necessarily approximate measures of vascular risk.  
Individual tests assess various aspects of vascular structure and function to 
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add weight to the knowledge of a persons’ CVD risk.   No single test gives a 
complete assessment of CVD.   
 
Cardiac catheter studies can demonstrate the vessel lumen, but these tests 
are expensive, invasive, have inherent risks and thus make them less useful 
for large scale progress studies.  Other tests, such as CT assessment of 
coronary calcium scores, have good correlation with CVD but are also 
expensive and expose the patient to significant levels of radiation.  
Functional tests identify disease in the setting of significant coronary 
stenosis, which implies the presence of advanced disease.  
 
Ultrasound provides a range of non-invasive techniques that assess 
peripheral vascular structure and function. It is commonly used to assess 
arterial structure and function by measuring arterial wall thickness, arterial 
wall reactivity and arterial stiffness. Observational studies have shown that 
these tests correlate well with future risk of CVD and current CVD burden.   
Atherosclerosis is a patchy process and it is difficult to gain an overall 
impression of the burden of disease.  It has been recognised that there is 
good correlation between the risk of CVD and the thickness of the arterial 
wall.  This thickness can be measured using ultrasound.  
  
Arteries are divided into three layers: the intima, media and adventitia.  
Ultrasound detects changes in tissue boundaries and as such can clearly 
delineate the discrete areas of the arterial wall.  This allows the thickness of 
the intima media to be measured.  Measurement of the carotid artery is 
preferred because it allows clear visualisation of a large calibre artery that is 
relatively superficial, parallel and has a distinct anatomical area, the carotid 
bulb, to provide a reference point, thus giving the most reliable data [128].  
 
Carotid ultrasonography has been used to obtain measurements of the 
thickness of the intima and media of the carotid arteries. Previous studies 
have shown cross-sectional associations between common-carotid-artery 
intima-media thickness and cardiovascular risk factors [129-131], the 
prevalence of cardiovascular disease, [130-132] and the involvement of 
other arterial beds with atherosclerosis [133] Changes in common-carotid-
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artery intima-media thickness (CIMT) have also been adopted as a surrogate 
end point to determine the success of interventions that lower the levels of 
low-density lipoprotein cholesterol [134, 135]. CIMT has been shown to be 
associated with diabetes, fibrinogen level, body mass index, and clinically 
overt atherosclerosis [136].  There is evidence that CIMT can predict an 
increased risk of future myocardial infarction and stroke.   
 
Increasing levels of CIMT are associated with an incremental risk of 
myocardial infarction and stoke. In one study, 5858 patients >65 years of 
age with no pre-existing cardiovascular disease were separated into quintiles 
on the basis of maximal CIMT, and followed for a mean period of 6.2 years. 
Over this period, 47 of 897 patients in the lowest quintile of IMT (<0.87 
mm) had a myocardial infarction or stroke. In comparison, those in the 
highest quintile of IMT ( 1.18 mm) had 167 events. This equated to an 
age- and sex-adjusted relative risk of 2.85 [93].  
  
In newly diagnosed patients with RA and subjects in a control group, a 
recent study found no signs of atherosclerosis; however after 18 months 
there was a significant increase in CIMT in RA patients compared to 
controls [137]. Hannnawi et el [138] found that CIMT was significantly 
increased in their early RA cohort compared to controls (0.64 ± 0.13 mm 
versus 0.58 ± 0.09 mm, P = 0.03). They repeated their analysis after 
removing patients with previous CV events and their controls and the results 
had not changed (0.63 ± 0.02 mm versus 0.57 ±0.01 mm, P = 0.03). There 
are few studies investigating CIMT in early RA, indicating a need for 
further studies of CIMT in early and longstanding RA.  
 
1.16 Kynurenine pathway  
The kynurenine (KYN) pathway is a metabolic pathway leading to the 
production of nicotinamide adenine dinucleotide (NAD) from the 
degradation of the essential amino acid enzyme tryptophan (TRP) (Figure 
3). The oxidation of TRP, initiating the KYN pathway, may be catalysed by 
one of three enzymes – tryptophan 2,3 dioxygenase (TDO) residing 
predominantly in the liver, indoleamine 2,3 dioxygenase 1 (IDO1) or a 
newly-discovered, related enzyme, indoleamine 2,3 dioxygenase 2 (IDO2) 
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[139-141].  IDO1 is the predominant extra-hepatic enzyme, found in 
numerous cells, including macrophages, microglia, neurons and astrocytes 
[142-145]. IDO1 is stimulated by the pro-inflammatory cytokine interferon 
γ (IFN ), which is activated by T lymphocytes during an immune response 
[146].    
 
  
Figure 1-6: Schematic diagram of the kynurenine pathway  
From : Int J Tryptophan. 2009; 2: 1-19 [147]  
  
1.17 Kynurenine in RA  
Through several pathways, KYN and its metabolites induce apoptosis of 
CD4+ Th1 T-cells and generation of Tregs, thereby providing negative 
feedback on T-cell responses. These effects may be helpful to maintain self-
tolerance and to limit inflammatory disorders, but little is known about the 
relationship between disease activity and KYN levels in RA patients.  
Furthermore, increased concentrations of KYN have been linked to tumour 
cell immune escape and to poor prognosis in cancer patients [148]. One may 
speculate that immune down-regulation by KYN could increase the risk of 
infections, especially viral infections, where Th1 T-cell responses contribute 
an important part of host defence.  
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Increased IDO activity may be measured as the KYN/TRP ratio.  In patients 
undergoing coronary angiography for suspected coronary artery disease, an 
increased KYN/TRP ratio in urine was strongly associated with major 
coronary events, acute myocardial infarctions, ischemic stroke, and all-
cause mortality [149]. Similarly, an increased ratio was linked with more 
advanced atherosclerotic changes in patients on chronic haemodialysis due 
to kidney failure [150].  In these settings, KYN may be acting as a 
biomarker of inflammation. Taken together, KYN may play various roles in 
the interactions among inflammation, immune dysregulation, CVD risk and 
possibly the risks of cancer and infections in RA patients.  
 
1.18 Rationale for the study  
There are several studies that have reported and demonstrated CVD in 
established and early onset RA patients, CIMT progression in patients with 
RA compared to the general population, and the relationship between IDO 
and or KYN/TRP ratio in RA patients. However there are very few studies 
reporting the association of CVD and risk factors such as inflammation as 
an increased risk for future development of RA, or comparing CIMT 
progression between RA and another chronic disease with similar CV risk, 
or demonstrating the relationship in KYN and CVD, new CV events, 
malignancy and death in RA patients. This thesis will address some of these 
issues by examining CVD and risk factors in patients who later developed 
RA, comparing CIMT progression in RA and T2D and investigating KYN 
concentration levels in RA patients.  
 
1.18.1 Aims  
Aim 1. To investigate the effects of CV risk factors, and CV events on the 
development of RA, using a population-based cohort study design. As a 
control to assess whether any findings were specific to RA or related to 
arthritis in general, a parallel investigation was undertaken in participants 
with and without osteoarthritis.  
Aim 2. To compare the characteristics of cardiovascular risk and 
progression of carotid intima-media thickness (CIMT) in individuals with 
RA and type 2 diabetes.  
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Aim 3. To measure serum kynurenine in baseline samples from an RA 
cohort with 10 year follow-up for cardiovascular events, and to investigate 
the relationship between kynurenine concentrations, malignancy, infection, 
cardiovascular disease and cause of death.  
These aims will be discussed in 3 separate chapters and will form the body 
of this thesis.   
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2.1  Abstract  
Objective:  Patients with rheumatoid arthritis (RA) have increased risk of 
cardiovascular (CV) events. We sought to test the hypothesis that due to 
increased inflammation, CV disease and risk factors are associated with 
increased risk of future RA development.  
Methods: The HUNT population-based health surveys were conducted 
among the entire adult population of Nord-Trøndelag, Norway to establish 
the health history of 75000 people. All inhabitants 20 years or older were 
invited, and information was collected through comprehensive 
questionnaires, a clinical examination, and blood samples. In a cohort 
design, data from HUNT2 (1995-1997, baseline) and HUNT3 (2006-2008, 
follow-up) were obtained to study participants with RA (n=786) or 
osteoarthritis (n=3586) at HUNT3 alone, in comparison with individuals 
without RA or osteoarthritis at both times (n = 33,567).    
 Results: Female gender, age, smoking, body mass index, and history of 
previous CV disease were associated with self-reported incident RA 
(previous CV disease: odds ratio 1.52 (95% confidence interval 1.11-2.07). 
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The findings regarding previous CV disease were confirmed in sensitivity 
analyses excluding participants with psoriasis (odds ratio 1.70 (1.23-2.36)) 
or restricting the analysis to cases with a hospital diagnosis of RA (odds 
ratio 1.90 (1.10-3.27)) or carriers of the shared epitope (odds ratio 1.76 
(1.13-2.74)). History of previous CV disease was not associated with 
increased risk of osteoarthritis (odds ratio 1.04 (0.86-1.27)).  
Conclusion: A history of previous CV disease was associated with 
increased risk of incident RA but not osteoarthritis.  
  
2.2 Introduction  
Rheumatoid Arthritis (RA) is a systemic, inflammatory autoimmune 
disorder that primarily involves the joints.  Despite treatment advances, RA 
patients continue to have higher mortality and morbidity rates than the 
general population, predominantly related to increased atherosclerotic 
cardiovascular (CV) disease [77, 151].   The traditional CV risk factors 
include age, gender, family history, smoking, diabetes, hypertension, 
dyslipidemia, obesity and sedentary lifestyle. RA patients carry a higher 
burden of some of these factors. The disease occurs most commonly after 40 
years of age and is associated with accelerated cellular ageing [152]. 
Smoking history is associated both with RA development and severity [43, 
153, 154]. Physical inactivity is common in patients with RA and may 
increase co-morbidity due to obesity or diabetes, leading to an increased risk 
of CV mortality [155]. Some studies have also suggested that myocardial 
disease without atherosclerosis is more prominent in RA patients. For 
example, an echocardiography study demonstrated that RA patients 
asymptomatic for CV disease had ischemia more frequently than controls, 
but they also had fewer significant angiographic coronary artery stenoses 
[156]. Likewise, an autopsy study showed that RA patients had diffuse 
myocardial fibrosis or non-specific myocardial degeneration more 
frequently than controls after excluding individuals with other known causes 
[157].   
 
Inflammation plays a central role in the pathogenesis of atherosclerosis, and 
the increase in CV disease and mortality in RA may partly be explained by 
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inflammatory factors associated with RA, even after adjustment for 
traditional CV risk factors [158, 159]. We and others showed that 
atherosclerosis is increased both in patients with established RA and at 
presentation in patients with recent-onset RA, as determined by increased 
carotid intima media thickness and plaque, and is associated with their 
inflammatory burden [160, 161]. The risk for MI and possible CV death is 
already increased within approximately 5 years after diagnosis of RA 
depending upon age and presence of CV risk factors, resulting in a 10-year 
absolute risk comparable to non-RA individuals who were 5-10 years older 
[14].  
 
It has been demonstrated that inflammation pre-dates the onset of RA [162].  
These data suggest that an increased risk of CV disease might also precede 
the onset of RA. The Rochester Epidemiology Project study demonstrated 
that RA patients were more likely to have been hospitalized because of MI 
prior to RA diagnosis [163].  However, a previous longitudinal cohort study 
found no difference in rate of MI, congestive heart failure or angina between 
pre-RA and control individuals [164].    
 
We hypothesized that CV risk factors and events are more prominent in 
persons with incident RA, and that this augments the risk of future RA 
development by increasing inflammation. The aim of the study was 
therefore to investigate the effects of CV risk factors and CV events on the 
development of RA, using a population-based cohort study design. As a 
control to study whether any findings were specific to RA or related to 
arthritis in general, a parallel investigation was performed in participants 
with and without osteoarthritis.   
  
2.3 Patients and methods  
The study participants were from the HUNT population-based health 
surveys conducted in the county of Nord-Trøndelag in Norway. The county 
is fairly representative for Norway as a whole, with a stable and ethnically 
homogenous population (3% non-Caucasians). All inhabitants 20 years or 
older were invited, and information was collected through comprehensive 
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questionnaires and a clinical examination. The HUNT2 survey has 
previously been described in detail [165]. The HUNT3 survey had a similar 
design. In total, about 75,000 (70% of those invited) participated in HUNT2 
(1995-1997), 51,000 (54% of those invited) participated in HUNT3 (2006-
2008), and 37,071 participated in both HUNT2 and HUNT3. By design the 
participants were not seen during the years between inclusion in HUNT2 
and HUNT3.  
 
The study cohort consisted of all participants in both HUNT2 and HUNT3 
who answered whether they had a diagnosis of RA or not (n=36,493, i.e. 
98.4% of 37,071) and this number determined the study size. Incident cases 
of RA were identified, i.e. participants who reported a diagnosis of RA in 
HUNT3 but not in HUNT2.  We also identified the incident cases of 
osteoarthritis for comparison, based on the question; “Has a doctor ever said 
that you have/have had any of these diseases: degenerative joint disease 
(osteoarthritis)?” The question also included the Norwegian colloquial term 
for osteoarthritis. Each patient group was compared to the remaining 
participants of the study cohort.    
 
Participants of HUNT gave informed consent. Approval for the study was 
obtained from the Regional Committee on Medical Research Ethics, Central 
Norway, the Norwegian Data Safety Authorities, and the Norwegian 
Department of Health. Ethics approval was also obtained by the Metro 
South Ethics Committee Brisbane. Permission was granted from the two 
primary hospitals in Nord-Trøndelag, Levanger and Namsos hospitals, and 
the nearest secondary referral hospital, Trondheim University Hospital, to 
link the identified RA cases in our study to the hospital diagnosis registries 
for verification of diagnosis. The registered diagnoses are used for billing 
and reimbursement from the national insurance scheme. The ICD-9 code 
714 and ICD-10 codes M05 and M06 with sub-codes were searched for. We 
did not have permission to access to the patients’ case notes in order to 
check that the current criteria for RA were correctly employed.    
 
On enrolment in HUNT2 and HUNT3 the participants completed a 
questionnaire incorporating information on medical history, smoking habits, 
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and family history of CV disease, defined as a parent, sibling or child with 
previous MI or stroke. Information on use of lipid-lowering medications or 
non-steroid anti-inflammatory drugs was not available. Anthropometric and 
clinical measures included height, weight, waist and hip circumference, and 
blood pressure. Non-fasting blood samples were drawn and total cholesterol, 
low-density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) 
cholesterol, triglycerides and serum glucose were measured using an 
autoanalyzer (Hitachi). Using DNA isolated at HUNT Biobank, participants 
with self-reported RA were genotyped for the Shared Epitope [166].  
Samples were genotyped using the Illumina Immunochip microarray chip, 
and HLA-DRB1 genotypes then determined by imputation using the 
program HLA-IMP [167, 168].  Autoantibodies (anti-citrullinated peptide 
antibodies or ACPA, rheumatoid factor) and C-reactive protein were not 
measured in this survey, and classification into seropositive or seronegative 
RA was not possible. Hypertension was defined as systolic blood pressure ≥ 
140 mmHg, diastolic blood pressure ≥ 90 mmHg or use of medication. 
Hypercholesterolemia was defined as total serum cholesterol > 6.2 mmol/L. 
Body mass index (BMI) was calculated as weight / height2 (kg/m2). Patients 
who reported using over-the-counter analgesics daily for 1 month or more 
during the last year before inclusion in HUNT2 were recorded as users of 
analgesics. Previous CV disease was defined as a composite of angina, MI 
or stroke. The relevant questions were; “Have you had or do you have 
angina pectoris?” “Have you had a stroke/brain hemorrhage?” and “Have 
you had a myocardial infarction?” The question about angina also included 
a Norwegian colloquial term for this diagnosis. The composite variable was 
used for previous CV disease as numbers of cases were too low for analysis 
of individual disease events. The level of missingness at baseline for most 
key variables was < 1%, with the exception of smoking (12.8% missing 
data). Missingness for smoking was evenly distributed among the subgroups 
of the study cohort. Non-complete cases were omitted from analysis.   
  
2.4 Statistical methods  
Data are presented as number (percentage), mean (standard deviation), or 
median (interquartile range), as appropriate. The chi-square test and the 
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Mann-Whitney U-test were used for between group comparisons of 
categorical and continuous study parameters, respectively.  Risk factors 
associated with the development of RA and osteoarthritis between HUNT2 
and HUNT3 were identified using multivariate logistic regression models. 
Linearity of logits for continuous variables was checked by plotting. P-
values <0.05 were considered significant. Pearson’s correlation coefficient 
R was calculated to evaluate linear correlation.    
 
Since this was a population-based survey and RA was self-reported, we 
performed several sensitivity analyses to support our main analysis. Because 
previous studies have indicated that few women with RA surveyed in the 
community report their diagnosis accurately [169], we repeated the analysis 
in several subgroups of the incident RA cases using additional criteria to 
remove false positive diagnoses, i.e. 1) excluding all who also reported 
having psoriasis (n=178), 2) including only patients where the diagnostic 
registries of the nearest hospitals showed a diagnosis of RA (n=216), 3) 
restricting the hospital-diagnosed cases to those where the diagnosis first 
occurred after 1999 or 4) after 2001, to avoid including patients who forgot 
to report RA in HUNT2, or 5) including only incident RA cases who carried 
the shared epitope (with and without additional exclusion due to a report of 
psoriasis). To represent the CV risk factors in another way, we developed 
alternative models including the Framingham risk score, which is based on 
age, serum cholesterol, hypertension, smoking and diabetes [170], as well as 
gender and history of CV disease. The Framingham risk score was preferred 
because it assigns higher risk with diabetes and there are no age limits, and 
because it may easily be calculated in large cohorts. The European 
HeartScore [171] is based on risk for patients between 40 and 65 years and 
requires separate input for each individual using charts or an online 
calculator, which was not practical in our large cohort. To verify that the 
Framingham risk score was applicable in our cohort, we calculated the PC-
based HeartScore for 50 randomly selected incident RA cases and 50 
controls [172]. Parallel Framingham risk scores and HeartScores were used 
to calculate an equation permitting estimation of the HeartScore in the entire 
cohort from their Framingham risk scores. An alternative logistic model was 
developed substituting the Framingham risk score with these estimated 
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HeartScores. In addition, we compared factors associated with incident 
cases of self-reported RA with incident cases of self-reported osteoarthritis.    
 
2.5  Results  
The baseline characteristics of the participants are presented in Table 1. At 
baseline (1995-1997) 33,567 participants reported not having RA, and of 
this group 786 (2.34%) reported RA at follow-up (2006-2008). This 
corresponds to an average annual incidence of 0.21% in women and 0.16% 
in men, respectively. If restricted to participants with cases identified in the 
local hospital registries (n=216), the annual incidence was 0.06% in women 
and 0.04% in men. As expected, incident cases of RA were older and more 
of them were current or previous smokers and had hypertension at baseline. 
Incident cases of RA had significantly elevated metabolic risk factors 
including blood pressure, BMI, serum cholesterol and triglyceride.  The 
estimated median (interquartile range) Framingham risk scores at baseline 
were 11 (7, 16) and 8 (4, 13) respectively in incident cases and those who 
did not develop RA. Notably, a higher proportion of incident RA cases had 
a history of CV disease at baseline.    
 
Female gender, age, smoking, BMI, and previous CV disease were more 
prominent in those developing RA (odds ratio 1.52 (1.11-2.07), Table 2, I - 
Main model). There was minimal change in the odds ratio for previous CV 
disease with inclusion of use of analgesics in this logistic regression model, 
when systolic and diastolic blood pressure were included as continuous 
variables instead of the categorical variable for hypertension, with 
additional adjustment for total cholesterol and HDL cholesterol 
concentrations, or when a variable for physical activity (low, moderate, 
high) was also included (data not shown).  In all the alternative multivariate 
models for incident RA where the number of patients was restricted to better 
characterized subgroups, previous CV disease was significant and the odds 
ratios were higher than for the main model including all self-reported cases 
(Table 2).      
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Table 2-1: Characteristics of individuals without rheumatoid arthritis (RA) or osteoarthritis (OA) at baseline  
 
  All  Later  Did  not  P-value  Later         Did not   P-value  
 participants  developed RA  develop RA   developed OA  develop  OA  
without  
RA/OA  
n  33567  786  32781    3586  29981    
Age (years)   46 (13)  51 (13)  46 (13)  **  52 (10)   45 (13)   **  
Sex (female)   18207 (54.2%)  488 (62.1%)   17719 (54.1%)   **  2406 (67.1%)  15801(52.7%)   **  
Smoking        **      **  
             Current   8901 (26.5%)  256 (32.6%)  8645 (26.4%)    1015 (28.3%)  7886 (26.3%)    
          Former  7908 (23.6%)    
 
212 (27.0%)  
 
7696 (23.5%)  
   
945 (26.4%)  
 
6963 (23.2%)  
  
Never smoker   15017 (44.7%)  281 (35.6%)   14736 (45.0%)    1425 (39.7%)   13592 (45.3%)    
Hypertension   12186 (36.3%)  339 (43.1%)   11847 (36.1%)   **  1547 (43.1%)   10639 (35.5%)   **  
Diabetes  454 (1.4%)  19 (2.4%)  435 (1.3%)  *  61 (1.7%)   393 (1.3%)     
Previous CV  
disease   
 
1060 (3.2%)  
 
52 (6.6%)   
 
1008 (3.1%)   
 
**  
 
158 (4.4%)   
 
902 (3.0%)   
 
**  
              Angina   673 (2.0%)  35 (4.5%)   638 (1.9%)   **  107 (3.0%)   566 (1.9%)   **  
MI  441 (1.3%)  16 (2.0%)  425(1.3%)     49 (1.4%)   392 (1.3%)     
              Stroke   223 (0.7%)  9 (1.1%)   214 (0.7%)    32 (0.9%)   191 (0.6%)     
Family risk of  
CV disease  
 
15692 (46.7%)  
 
414 (52.7%)   
 
15278 (46.6%)   
 
**  
 
2017 (56.2%)   
 
13675 (45.6%)  
 
**  
Framingham  
risk score2  
 
9 (4-13)  
 
11 (7-16)  
 
8 (4-13)  
   
11 (7-15)   
 
8 (3-13)  
  
Weight (kg)  76 (14)  77 (14)  76 (14)    77 (13)   76 (14)    
 
BMI2 (kg/m2)   25.6 (23.5- 
28.1)   
26.3 (24.3- 
29.0)  
25.6 (23.4- 
28.1)  
 
**  
 
26.4 (24.2-29.0)  
 
25.4 (23.3-27.8)  
 
**  
Waist 
circumference  
(cm)   
 
85 (11)  
 
86 (11)  
 
85 (11)  
 
*  
 
86 (11)  
 
85 (11)  
 
**  
Hip circumference 
(cm) 102 (8)  103 (8)  102 (8)  **  103 (8)  101 (6)  **  
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1Values are mean (standard deviation) or numbers (%), or 2median (interquartile range). Non-respondents were excluded. CVD=cardiovascular 
disease. MI=myocardial infarction. BMI=body mass index.  HDL=high density lipoprotein. * p-value <0.05, ** p-value <0.001, comparing individuals 
who developed RA and did not develop RA, or comparing individuals who developed OA and did not develop OA. All blood samples were non-
fasting.  
  
II – Alternative models A to F). A diagnosis of RA was confirmed in the 
hospital registries for 216 participants (27%) who had self-reported a new 
RA diagnosis in HUNT3. The characteristics of these participants were very 
similar to those reported for the entire group of incident RA cases (data not 
shown). In the 216 cases with a hospital diagnosis of RA, the diagnosis was 
found 1-2 years following enrolment in HUNT2 for 14 cases (6.5%), after 3 
years for 24 cases (11.1%), after 4 years for 15 cases (6.9 %), after 5 years 
for 28 cases (13.0%), and after 6 years for 22 cases (10.2 %). For the 
remaining 113 cases (52.3%), the times were distributed from 7 years 
onwards to the inclusion in HUNT3 with numbers varying unsystematically 
from 15 to 24 cases (6.9-11.1%) per year.  Thus, there was no obvious 
pattern regarding the number of years from HUNT2.   
 
In a separate alternative multivariate logistic regression model containing 
gender, previous  CV disease, and the Framingham risk score as covariates, 
the odds ratio for developing RA in subjects with previous CV disease was 
1.65 (1.21-2.24)(p<0.01). This model also suggested the likelihood of 
developing RA was 6% greater with each 1 unit increase in Framingham 
risk score (odds ratio: 1.06, 95% CI: 1.05-1.08), p<0.001). The model did 
Waist/hip ratio  0.84 (0.08)  0.84 (0.08)  0.84 (0.08)    0.83 (0.07)
  0.84 (0.08)  **  
        
Systolic blood 
pressure2 (mmHg)   
 
 
131 (120-144)  
 
 
133 (122-146)  
 
 
131 (120-144)  
 
 
*  
 
 
133 (122-147)  
 
 
131 (120-143)  
 
 
**  
Diastolic blood 
pressure  
(mmHg)   
 
79 (11)  
 
80 (11)  
 
79 (11)  
 
*  
 
81 (11)   
 
79 (11)  
 
**  
Serum cholesterol 
(mmol/L)   
 
 
5.8 (1.2)  
 
 
6.0 (1.2)  
 
 
5.8 (1.2)  
 
 
**  
 
 
6.1 (1.2)   
 
 
5.8 (1.2)  
 
 
**  
HDL cholesterol  
(mmol/L)   
 
1.40 (0.39)  
 
1.37 (0.39)  
 
1.40 (0.39)  
   
1.44 (0.40)   
 
1.39 (0.38)  
 
**  
Serum  
triglycerides2  
(mmol/L)  
 
1.40 (0.98- 
2.07)  
 
1.51 (1.10- 
2.24)  
 
1.40 (0.97- 
2.06)  
 
**  
 
1.46 (1.02-2.12)   
 
1.37 (0.95-2.04)  
 
**  
 38  
not change with adjustment for BMI or daily use of over-the-counter 
analgesics. In the model where the Framingham risk score was substituted 
with the estimated HeartScore, previous cardiovascular disease remained 
significant (odds ratio: 1.70 (1.25-2.32), p<0.01). In the 100 participants 
where the HeartScore was calculated using the PC-based calculator, the 
HeartScore (logarithmically transformed) was highly correlated with the 
Framingham risk score (R=0.86, p<0.001). The correlation was very similar 
in patients (R=0.89) and controls (R=0.86).   
    
Table 2-2: Effects of risk factors on incident RA and osteoarthritis, by multivariate logistic regression  
I - Main model – Rheumatoid arthritis (n=739 patients and 30,829 controls)1   
 
CI = Confidence Interval 
  
 Odds 
Ratio 
 95% CI P-Value 
Female gender    1.50      1.29-1.75   <0.01 
Age2      1.03     1.02-1.04   <0.001 
Current smoker    1.64     1.38-1.96   <0.001 
Former smoker    1.32     1.10-1.59   <0.01 
Hypertension    0.97     0.82-1.15   0.76 
Diabetes    1.34   0.83-2.18     0.23 
Body mass index2   1.04   1.02-1.06     <0.001 
 
 
Previous CV disease 
  
 
 
 
1.52 
 
  
  
 
 
 1.11-2.07 
 
  
 <0.01 
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Alternative models (sensitivity analyses) - Rheumatoid arthritis  
    Odds Ratio 95% CI  P-Value 
A – After exclusion of patients with self-reported psoriasis (n=573 patients and 30,829 controls)1  
 Previous CV disease3  1.70                  1.23-2.36               0.001  
B – Including patients with hospital diagnosis of RA (n=201 patients and 30,829 controls)1  
  Previous CV disease3  1.90                   1.10-3.27             0.02     
C – Including patients with hospital diagnosis of RA after 1999 (n=178 patients and 30,829 controls)1  
  Previous CV disease3  2.26                    1.26-3.99                   <0.01  
D – Including patients with hospital diagnosis of RA after 2001 (n=138 patients and 30,829 controls)1  
  Previous CV disease3  2.51                     1.33-4.73                    <0.01  
E – Including patients carrying the Shared Epitope (n=313 patients and 30,829 controls)1  
  Previous CV disease3  1.76                      1.13-2.74                   0.01  
F – Including patients carrying the Shared Epitope and excluding patients with self-reported  
             Psoriasis  (n=257 patients and 30,829 controls)1  
  Previous CV disease3  1.96                       1.24-3.10                     <0.01    
II – Model for osteoarthritis (n = 3364 patients and 24,631 controls)1   
 Odds 
Ratio 
 95% CI P-Value  
  Female gender    2.36    2.15-2.56   <0.001   
  Age2      1.05    1.05-1.06   <0.001   
  Current smoker   1.42    1.30-1.56   <0.001   
  Former smoker    1.23    1.12-1.35   <0.001   
  Diabetes     0.90    0.66-1.22   0.49   
  Body mass index2  1.06    1.05-1.07   <0.001   
  Previous CV disease  1.04    0.86-1.27   0.66   
                                                 
1 Cases with complete data, 2Continuous variable, Odds ratio per 1 unit change, 3Multivariate model including the same 
variables as the main model for RA  
    
 40  
At follow-up (2006-2008), 3,586 participants had developed osteoarthritis, 
corresponding to an average annual incidence of 1.05% in women and 
0.64% in men respectively. These patients were older and the proportion of 
smokers, former smokers and of those with hypertension was higher than in 
the group that did not develop osteoarthritis. Systolic and diastolic blood 
pressure, BMI, hip and waist circumference, total cholesterol and 
triglycerides were higher for incident cases of osteoarthritis, whereas HDL 
cholesterol was lower in incident cases of osteoarthritis. Female gender, age 
and smoking were associated with development of osteoarthritis, whereas 
previous CV disease was not (Table 2. III).   
  
2.6  Discussion  
In the present large population-based health study we found that participants 
who developed RA between HUNT2 and HUNT3 had more CV disease and 
CV risk factors prior to the onset of RA (at HUNT2) compared to those 
without incident RA. A history of CV disease was a significant risk factor 
for incident RA, as well as the previously reported risk factors: female 
gender, increasing age, increasing BMI and smoking [173]. The finding of a 
positive association with the Framingham risk score may be related to 
smoking and age being incorporated into the score. The supplementary 
analysis showed that the Framingham score was equivalent to the estimated 
HeartScore in our population even though the Framingham score was not 
developed from European subjects. On the other hand, previous CV disease 
events did not contribute to the risk of future osteoarthritis in our study, 
indicating that the finding may be specific to RA. Smoking was associated 
with incident osteoarthritis.   
  
2.6.1 CV disease and incident RA  
The design of our study has several strengths. Since the data on the CV risk 
factors and events were collected at HUNT2, recall bias at HUNT3 was 
greatly reduced compared to a design where patients report on these factors 
when receiving an RA diagnosis at a hospital-based clinic. Furthermore, the 
observation time between HUNT2 and HUNT3 was approximately 10 
years. The importance of a long observation time is underscored by the 
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finding that the odds ratio for the association of incident RA with previous 
CV disease increased when patients receiving a hospital diagnosis of RA 
during the first years following HUNT2 were excluded. It also seems 
biologically plausible that longer exposure to increased inflammation due to 
CV disease further increases the risk of incident RA. Furthermore, the 
statistical power is greatly improved in a population-based cohort study due 
to the large number of controls, and problems defining a relevant control 
group as seen with case-control studies of RA are avoided.  
  
The major limitation of our study is that data were self-reported. Previous 
studies suggest that self-reported CV diagnosis and risk factors such as 
hypertension and cigarette smoking are reliable [174, 175]. However, the 
high incidence rate of self-reported RA in our study compared for example 
to recent Swedish data based on inpatient and non-primary outpatient care 
(0.056% in women, 0.025% in men) [176], confirms that there probably 
were many false-positive RA diagnoses. This would tend to decrease the 
power to detect true positive results in our study, but not bias towards false 
positive findings. When including only cases identified in the hospital 
registries, the incidence was close to the Swedish data. Furthermore, the 
incidence of RA increases with observation time [177]. Therefore different 
data may not be directly comparable.   
 
Epidemiological studies also carry a risk of reverse causation, which could 
ensue if persons with undiagnosed RA in HUNT2 were erroneously 
included as incident cases of RA, because RA in itself increases the risk of 
CV disease and events [178]. It seems unlikely that reverse causation could 
explain our findings, given that the association with previous CV disease 
became stronger when the cases with shortest duration between HUNT2 and 
a hospital diagnosis of RA were removed from the analysis. Furthermore, 
we did not observe a tendency for a higher number of cases with a hospital 
diagnosis to occur during the earliest years following HUNT2, which would 
have been expected with substantial reverse causation.   
 
While fatal CV events prior to onset of RA also limited the participants in 
our study to survivors of those events, this again would lead to under-
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estimation of the impact of CV events on development of RA, or to restrict 
the population at risk of RA to those ageing with CV risk that was 
insufficient to lead to premature mortality. Autoantibodies were not 
measured and seropositive and seronegative cases of RA could not be 
distinguished, which impacts on the generalizability of our results compared 
to others, such as population-based cohorts where it was concluded that 
ischemic heart disease was not increased prior to RA onset [164]. There 
may also have been a selection bias regarding participation in HUNT, where 
sicker people or those with a lower socioeconomic status are less likely to 
join. These people have a higher risk both for CV disease and for RA, which 
may have biased our findings.   
 
The results from our various sensitivity analyses unanimously supported our 
main analysis. The overall conclusion that a history of CV disease is 
associated with the risk for incident RA therefore seems reliable. Although 
our study may not be suitable to give an exact estimate of the size of this 
increased risk, the main analysis giving an OR of approximately 1.5 is 
probably conservative.   
 
2.6.2 Risk factors for osteoarthritis  
Our results identifying smoking as a risk factor for future osteoarthritis 
contradict some previous studies, which report an inverse association 
between smoking and osteoarthritis [179]. However, the longitudinal 
prospective Clearwater study designed to identify risk factors for OA 
development, which included 2,505 participants, did not support this inverse 
association with smoking for any of four joint sites (knee, hand, foot or 
spine) [180]. In another prospective study of 1,003 participants from the 
general population there was no association between smoking and 
radiologically confirmed OA at different sites [181]. The current study may 
have shown an association with smoking because it is larger and included a 
greater number of incident osteoarthritis diagnoses. Nevertheless, since our 
study relies on self-report, replication in a cohort ascertained for 
radiographic osteoarthritis and symptoms is needed.  However in support of 
the accuracy of our case classification, we noted that higher BMI increased 
the risk for osteoarthritis development, as previously described [182].   
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2.6.3 Inflammation as a link between CV disease and incident RA  
From a biological perspective based on the current studies, we hypothesize 
that inflammation may contribute to the parallel development of 
atherosclerosis and RA during the pre-clinical period in individuals exposed 
to common RA and CV risk factors, just as this interaction accelerates 
complication of RA by CV events after onset.    
 
 
Figure 2-1: Proposed model for illustrating the relationship among RA, CV disease, 
inflammation, atherosclerosis and predisposing factors  
 
Inflammation is the most plausible link between previous CV disease or 
BMI and increased risk for RA. It is well established that the pathogenesis 
of CV disease, i.e. atherogenesis, includes chronic inflammation of the wall 
of muscular arteries and that inflammation is increased during acute 
coronary events, associated with unstable plaque and thrombosis [163]. 
Furthermore, obesity induces chronic inflammation in adipose tissue, 
increasing pro-inflammatory cytokines including interleukin-6 and tumour-
necrosis factor [183]. In addition, a pro-inflammatory state is present before 
the clinical onset of RA.   
 
CRP levels were found to be higher in individuals with pre-clinical RA 
compared to a control group [184]. Serum cytokines and chemokines were 
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also elevated preceding the onset of RA [185]. In at least some patients, 
periodontal inflammation may precede the onset of RA symptoms, also 
associated with ACPA [186]. Respiratory inflammation has also been 
described in ACPA positive individuals without RA [187]. Autoantibodies 
may also increase the risk of immune complex mediated vascular 
inflammation [188]. Thus, CV disease and CV risk factors increase the 
future risk of RA development in the context of systemic inflammation and 
autoantibody development [160]. Patients with seropositive RA are at 
greater risk of CV disease [43, 78], and it is possible that the RA genetic 
background is more permissive to atherosclerosis when associated with the  
“lifestyle” factors described here. In contrast to RA, in osteoarthritis 
inflammation is local and low-grade rather than systemic, and is not 
associated with autoantibodies.    
 
Figure 1 proposes a model for the relationships among RA, CV disease, 
inflammation and various predisposing factors, based on the results from the 
present study, as well as previous studies demonstrating an increased risk of 
CV disease after diagnosis of RA. Given that our findings were robust when 
adjusting for known risk factors for RA, this hypothesis merits further 
investigation in studies designed to clarify pathogenetic mechanisms, which 
is not possible in an epidemiological study.   
  
2.7  Conclusions  
A history of previous CV disease was associated with increased risk of 
incident RA but not osteoarthritis. A probable explanation is that increased 
systemic inflammation may contribute to the parallel development of 
atherosclerosis and RA during the pre-clinical period in individuals exposed 
to common RA and CV risk factors, in a similar way that such interaction 
accelerates CV disease in patients with established RA. The association of 
previous CV events with the development of RA at the population level 
suggests presentation with CV events, especially in middle-aged female 
smokers or first-degree relatives of RA patients, should raise clinical 
suspicion to capture cases of undiagnosed early RA. Because CV risk 
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factors are increased at onset of RA, active cardiovascular risk management 
is important from the time of diagnosis.   
 
Transition to chapter 3 
We and others have previously reported that CVD was present in patients as 
early as at diagnosis of RA and in established RA patients. There are few 
studies comparing CIMT in RA patients compared to other diseases of 
similar CV risk. Therefore with the information from this chapter we 
decided to compare CIMT in RA patients to patients with T2D. 
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Chapter 3: T2D patients have a higher risk of 
carotid-intima media thickness progression than RA 
patients  
  
3.1  Background    
It is well known that patients with Rheumatoid Arthritis (RA) or type 2 
diabetes (T2D) have increased risk of atherosclerosis and cardiovascular 
disease (CVD). Carotid ultrasound measurement of the intima media 
thickness (CIMT) is the most commonly used method to validate 
progression of atherosclerosis.   
 
Aim:   To compare the characteristics of cardiovascular risk and progression 
of CIMT in individuals with RA and T2D.  
 
Methods: We measured CIMT using B-Mode ultrasonography of the 
common carotid artery, in 290 individuals (78 RA patients and 212 T2D 
patients). RA patients were attending routine clinic appointments and T1D 
patients were assessed as part of a lifestyle intervention study.  We carried 
out a physical assessment, routine laboratory investigations and took a 
history of CV risk profile in all participants. CIMT was measured twice in 
individuals with RA and individuals with T2D, at a mean interval of 4.8 and 
2.4 years respectively.  
Results: The study comprised 290 individuals: 78 with RA and 212 with 
T2D. The RA cohort was older and had a higher proportion of smokers and 
previous CVD. The T2D cohort had higher BMI, diastolic blood pressure 
and triglycerides, lower HDL cholesterol and more statin use.   
At baseline, CIMT measurements were similar in the RA and T2D cohorts 
(0.88 (0.19) mm vs. 0.86 (0.21) mm p=0.80) respectively. In an adjusted 
linear regression model, RA was significantly associated with lower CIMT 
at follow-up (p<0.0005). Despite a shorter follow-up, 91 % of the T2D 
cohort had increased CIMT at follow-up compared to 54 % of the RA 
cohort (p<0.0005). In a supplementary adjusted logistic regression analysis 
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where the outcome was CIMT progression compared to unchanged or 
reduced CIMT, the OR for progression in T2D was 11.4 (5.2-25.0) 
compared to RA. In the RA cohort, DMARD use at baseline was associated 
with significantly lower CIMT values at follow-up (p=0.04).   
 
Conclusion: T2D patients have a much higher risk of CIMT progression 
than RA patients when adjusting for relevant risk factors and baseline 
CIMT.   
    
3.2  Introduction:  
There is substantial evidence that cardiovascular (CV) risk in RA is 
increased [189, 190]. However, whilst individuals with rheumatoid arthritis 
(RA) have higher carotid intima media thickness (CIMT) [138, 191] and 
develop more CV events than the general population [192, 193], it is not 
clear how rapidly cardiovascular disease (CVD) progresses relative to other 
diseases at increased CV risk. Patients with type 2 diabetes (T2D) also have 
an increased risk of CVD and diabetes is an independent risk factor for CV 
complications [194]. Diabetic patients without a prior history of myocardial 
infarction (MI) have the same risk for future events as non-diabetic patients 
who have had a prior MI [195]. Traditional CV risk factors and 
inflammation contribute to this increased risk in patients with RA and 
diabetes [196-199]. Obesity promotes insulin resistance, and obesity-related 
inflammation contributes to metabolic impairment and the risk of 
development of T2D [200, 201]. Several studies have shown associations 
between CIMT and CVD [129-131]. CIMT values measured by ultrasound 
have been shown to correlate with direct measurement of local and systemic 
atherosclerotic burden in pathology studies and with clinical CV endpoints 
[202, 203]. Current CVD burden B-mode ultrasound is also commonly used 
to assess arterial structure and function by measuring arterial wall thickness, 
arterial wall reactivity and arterial stiffness [204206].  
 
We found recent-onset RA patients had increased CIMT compared to 
healthy controls [138]. Similar increases were reported in patients with 
long-standing RA [191] and in T2D [207]. A recent study comparing T2D 
patients from the Hoorn study and RA patients from the Care study reported 
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that RA and T2D had similar CVD outcomes [208], however the pattern of 
CVD manifestations differed with RA having more coronary artery disease 
and T2D with more peripheral arterial disease [208]. Although RA and T2D 
may share some CV risk factors, differences exist, including presence of 
high-grade inflammation amongst those with RA [209].  Few studies have 
compared CIMT progression in two chronic diseases with elevated CV risk. 
With this in mind, the objective of the current study was to compare the rate 
of progression of CIMT in RA and T2D patients drawn from the same 
geographic location and in whom CIMT was measured using the same 
instrumentation and analysis techniques, and to relate this to CVD risk 
profile and CV events.  
  
3.3 Materials and Methods  
3.3.1 Participants  
Participants consecutively attending an outpatient Rheumatology clinic at a 
tertiary hospital in Brisbane Australia diagnosed with RA by a 
rheumatologist according to the American college of Rheumatology (ACR) 
1987 criteria [44], were recruited. A health assessment and CV 
questionnaire was completed by each individual. Demographic information 
was ascertained by a questionnaire and disease duration was determined by 
the length of RA symptoms. Patients were treated according to a response-
driven step-up algorithm [210]. Most participants were treated with a 
disease-modifying anti-rheumatic drug (DMARD) or a biologic agent at 
baseline.  
 
Participants with T2D were recruited from hospital community diabetes 
clinics in the same geographic area as RA participants. The participants with 
T2D participated in a randomised trial of exercise intervention for 4 weeks. 
248 patients underwent screening for occult coronary artery disease using 
exercise echocardiography, which excluded 25 patients. Of the 223 patients 
only 212 had readable CIMT measurements [211].  
 
All patients provided formal written consent for the carotid ultrasound 
measurements. Ethical approval for the current study was obtained from the 
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Metro South Human Ethics Committee. The CIMT was reported previously 
in some of the RA patients [138].   
  
3.3.2 Cardiovascular risk factor measurement:  
For the RA patients cigarette smoking status was obtained by questionnaire, 
which included past and present smoking history (1). In T2D patients, 
present smoking status was determined by reviewing patient medical notes. 
Body mass index (BMI) was calculated as weight (kilograms) divided by 
the square in height (metres). Fasting lipid, erythrosedimentation rate (ESR) 
and C-reactive protein (CRP) measurements were collected by the hospital 
pathology department on both the RA patients and T2D patients at baseline. 
Fasting glucose, insulin and HbA1c measurements collected in T2D patients 
were measured prior to and after the 4-week intervention period. Blood 
analyses were conducted using standard procedures by the Queensland 
Health Pathology Service (Brisbane, Australia), and all measurements were 
taken after an overnight fast and at least 24 h after the last exercise session. 
Insulin sensitivity [HOMAIR (homoeostasis model assessment of insulin 
resistance) and QUICKI (quantitative insulin check index)] and β-cell 
function [HOMAβ-Cell (homoeostasis model assessment of β-cell 
function)] were determined using formulae derived previously [273, 274].  
 
 In the RA patients, diagnosis of diabetes was by a physician or use of 
insulin or oral hypoglycaemic medications. Hypercholesterolemia and 
hypertension were identified if the diagnosis was recorded in medical notes 
by a physician or patients were taking lipid-lowering or anti-hypertensive 
medications at the time of assessment.  
  
3.3.3 Cardiovascular events  
To ascertain CV events, a CV questionnaire was completed by the patients 
for history, dates and treatments of MI, angina and stroke, as previously 
described (2) and these events were verified by reviewing the medical 
records. Patients with multiple events had only one event counted per 
person. MI was identified if patients developed either of the following 
clinical signs: a typical rise and fall in the levels of biochemical markers 
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consistent with myocardial necrosis, in addition to ischemic symptoms, 
development of pathologic Q waves on the electrocardiogram (ECG) and/or 
ECG changes indicative of ischemia (ST-segment elevation or depression); 
or either new pathologic Q waves on serial ECGs or pathologic changes of 
healed or healing MI [212]. Stroke was identified if patients had been 
admitted to the hospital with evidence of ischemic occlusion on computed 
tomography (CT) scanning, carotid endarterectomy, or symptoms of stroke, 
evidence of a significant plaque on carotid ultrasound and neurologic 
sequelae, with the exclusion of subarachnoid haemorrhage and space-
occupying lesions.  For the exercise intervention study in patients with T2D, 
those with serious co-morbidity or known CVD had been excluded [211]. 
CV events occurring after the baseline CIMT measurement were determined 
in patients with RA and T2D by review of hospital charts.   
  
3.4 Measurement of intima media thickness   
This hospital uses protocols established by The American College of 
Echocardiography (ASE) for measuring CIMT [213]. CIMT was measured 
from ultrasound images as earlier described using carotid duplex scanning 
and automated software [138]. Ultrasound images were frozen by ECG 
triggering (top of R-wave) to minimize variability depending on changes in 
the CIMT and lumen diameter occurring during the cardiac cycle [138, 214, 
215]. Offline analysis of the images was performed on a workstation using 
standard software for automated measurement of the intima-media thickness 
(IMT) (QLab 4.2.1 with IMT plugin, version 1.1; Philips Ultrasound, 
Bothell, WA, USA). The algorithm uses a maximum-slope edge-detection 
technique, beginning in the vessel lumen and detecting the first maximum 
slope of the change in signal for the near and far walls, and repeating the 
analysis to identify the media–adventitia interface. The software calculates 
the mean and standard deviation for the IMT thickness in a region-of-
interest box, placed by the observer perpendicular to the vessel walls, with 
the measurements performed on the R-wave of the ECG [138].  
 
Examination and analysis of the CIMT were performed by sonographers BH 
and LS, both from the same institute. The intra-observer variation and the 
co-efficient of variance was 0.01 ± 0.05 mm (5%) [138]. Data are given as 
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the total average CIMT over all measured vascular segments from anterior, 
lateral and posterior views from both the right and left common carotid 
arteries (n=6). Areas with plaque were not included and not quantified.  
  
3.5 Statistical analysis  
Analyses were performed with IBM SPSS (v.20), STATA (v.13.1) and the 
rms package in the statistical environment R. Data are presented as mean 
(SD) or median (inter-quartile range), or numbers (percentages). The t-test 
or Mann-Whitney U-test was used to compare continuous variables and the 
chi2 –test was used to compare frequencies between patients with RA and 
T2DM.  
 
Correlations between quantitative variables were analysed by Pearson’s 
correlation coefficient. P-values <0.05 were considered significant.  
We under took multivariable robust linear and logistic regression modelling. 
The model included pre-defined variables to analyse the CIMT 
measurements, as univariate screening carries a risk of overfitting. 
Transformation to normality was performed if necessary, and baseline 
CIMT was included as a covariate because we expected an association with 
follow-up CIMT. For linear regression, model fit was checked by residual 
plotting. For logistic regression, linearity of logits for continuous variables 
was checked by addition of spline terms.    
 
For comparison between the RA and T2DM groups, the main outcome was 
the mean follow-up   CIMT. Secondary analyses were performed using the 
average yearly rate of change in CIMT as outcome, and alternatively using 
progression (positive mean yearly rate of change) or no progression (zero or 
negative mean yearly rate of change) as outcome in logistic regression. For 
comparisons between the two patient groups, adjustments could only be 
made for variables available in both groups, i.e. age, sex, blood lipids, BMI, 
blood pressure, smoking, ever use of statins, and time to follow-up. Because 
the RA and T2DM groups were not matched, we also performed sensitivity 
analyses on a subgroup of the patients, matching each RA patient to a 
T2DM patient of the same sex and age (+ 2 years). For 3 RA patients (2 
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women aged 74 and 75 years and 1 male aged 78 years), matching by age 
was not possible and these cases were omitted from the sensitivity analyses.     
We used STATA to calculate Framingham Risk Score (FRS) as an 
alternative way to represent CV risk [170]. A sensitivity analysis was 
undertaken for CIMT at follow-up using CIMT at baseline, ever use of 
statins, RA/T2D and the FRS as covariates. Age and sex were not included 
because they are used in the calculation of the FRS.  
 
For analysis of medication effects on CIMT at follow-up in the RA patients, 
a step-wise modelling approach was used in order to reduce the final 
number of adjustment variables. This avoided overfitting due to a small 
sample size. In the first step, only baseline CIMT and classical risk factors 
were included, i.e. age, sex, diabetes (no/yes), smoking, hypertension, BMI 
and total cholesterol/HDL cholesterol ratio. The significant variables were 
included in the next step together with factors related to RA severity: RA 
duration, baseline ESR and baseline CRP. Again, only significant factors 
were carried on to the third step where we also included the variables of 
main interest, i.e. ever use of statins (no/yes), ever use of prednisone 
(no/yes), and baseline use of all or a combination of disease modifying anti-
rheumatic drugs (DMARDs) i.e. methotrexate, hydroxychloroquine and 
sulphsalazine (no/yes). The coding of statins and prednisone was chosen 
because changes in medication during follow-up may have influenced 
CIMT at follow-up and detailed information on dosage was not available. 
Baseline DMARD use was chosen because we hypothesized early treatment 
to be beneficial. In alternative models, baseline DMARD use was 
exchanged with ever use of DMARDs or DMARD use at follow-up.    
  
3.6  Results  
3.6.1 Sample characteristics  
The studied population consisted of 290 individuals, 78 with RA and 212 
with T2D who had all undergone carotid ultrasonography for measurement 
of CIMT at two time points: mean 4.8 years apart in RA patients and 2.4 
years apart in T2DM patients (p=0.001). Baseline characteristics of the 
participants are presented in Table 1. The two analysis time points are 
designated baseline and follow-up. Recruitment of patients occurred at a 
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new-onset or a follow-up clinic appointment, thus did not necessarily occur 
at diagnosis. The median disease duration for the RA group at follow up 
was 19.1 yrs (9.9-28) yr and for the T2D group was 6.4 (3.4-12.4) yrs (p= 
0.0005) respectively.   
 
The burden of CV risk factors varied between the two patient groups at 
baseline. The RA group was older, and had higher proportions of females, 
smokers, and previous CV events. The T2D group had higher mean BMI, 
diastolic blood pressure and triglycerides, lower HDL cholesterol and higher 
statin use (Table 1).  
 
At follow-up, HDL cholesterol remained lower, and systolic and diastolic 
blood pressure, BMI and triglyceride levels were higher in T2D than RA 
patients (Table 1). Although LDL cholesterol had decreased at follow-up for 
both RA and T2D patients, LDL cholesterol levels were higher in RA than 
T2D patients (Table 1). These data indicate that CVD risk factors were 
present in each group but the distribution of risk factors differed between 
groups.    
  
3.7 Comparison of CIMT in RA and T2D patients  
The mean CIMT at baseline was 0.88 (0.19) mm in the RA group and 0.86 
(0.21) mm in the T2DM group (p=0.80). The mean CIMT at follow-up was 
0.92 (0.16) mm in the RA group and 1.12 (0.25) mm in the T2DM group 
(p=0.001). In multivariable linear regression adjusted as previously 
described, higher follow-up CIMT was significantly positively associated 
with higher baseline CIMT (p<0.0005), age (p<0.05), diabetes (p<0.0005) 
and ever use of statins (p<0.05) (Figure 1). Time to follow-up was not 
significantly associated with CIMT at follow-up (p=0.94).  The median FRS 
was higher for T2DM 16 (16-17) than for RA 13 (12-14) (p<0.001). In the 
sensitivity analysis including the FRS instead of separate cardiovascular risk 
factors, the FRS was not significant (p=0.32) and there were only minimal 
changes in the coefficients for the significant variables mentioned above.     
The mean yearly rate of CIMT change was 0.003 (-0.009-0.024) mm in the 
RA group and 0.088 (0.054-0.170) mm in the T2D group (p<0.0005). In the 
regression model for yearly rate of CIMT change, the only significant 
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variables were diabetes (p<0.0005) and ever use of statins (p=0.01).  
Notably, baseline CIMT was not significantly associated with the yearly rate 
of CIMT change (p=0.52). With correction for multiple comparisons, 
however, the differences between statin users and non-users within each 
diagnosis group was no longer significant (Figure 2).   
 
193 (91%) of the T2D patients had CIMT progression over the follow-up 
period as opposed to 42 (54%) of the RA patients (p<0.0005). In logistic 
regression, progression of CIMT was associated with diabetes (p=0.001, 
odds ratio: 6.34 (2.17-18.50)) and ever use of statins (p<0.01, odds ratio: 
2.96(1.41-6.22)). Time to follow-up was not significant (p=0.23). This 
model was adjusted for baseline CIMT, hypertension, smoking and BMI.   
Given the differences in age and gender among RA and T2D groups at 
baseline and the potential for these to skew CIMT, we carried out a 
sensitivity analysis, in which data from 75 pairs of RA and T2DM patients 
matched for age and gender were compared. The average CIMT at baseline 
was 0.89 (0.17) mm in the RA group and 0.90 (0.17) mm in the matched 
T2D group (p=0.43). The average CIMT at follow-up was 0.92 (0.16) mm 
in the RA group and 1.15 (0.23) mm in the matched T2D group (p<0.0005). 
The average yearly rate of CIMT change was 0.003 (-0.002-0.012) mm in 
the RA group and 0.088 (0.076-0.113) mm in the matched T2DM group 
(p<0.0005). In the matched pairs, 72 (96%) of the T2D patients had CIMT 
progression over the follow-up period as opposed to 40 (53.3%) of the RA 
patients (p<0.0005). The findings using linear and logistic regression 
modelling were very similar to those reported above for the complete study 
cohort (data not shown).   
  
3.8 Influence of medication on CIMT in RA patients  
Characteristics of the RA patients are given in Table 2. At baseline, 7 
women (13.5%) and 7 men (26.9%) (p=0.14) were not using DMARDs.   
Using the described stepwise approach for the linear regression model for 
follow-up CIMT in the RA patients, age, sex, smoking and baseline CIMT 
were carried on from step 1 and no factors related to RA severity were 
significant in step 2. In the final model from step 3, baseline use of 
DMARDs (p=0.02), and the interaction between baseline CIMT and gender 
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(p=0.03) were significantly associated with follow-up CIMT (Figure 3). 
Baseline use of DMARDs had a protective effect but ever use of prednisone 
was not significant (p=0.44). If RA duration was added to the final model, 
this was not significant (p=0.84). In alternative models, ever use of 
DMARDs or use at follow-up were not significant contributors to follow-up 
CIMT (p=0.28 and 0.27, respectively).   
  
3.9  CV events  
CV events were self-reported by our RA patients, and confirmed by 
reviewing all medical records.   
At baseline, 16.7% of RA and no T2DM patients had experienced a CV 
event. At follow-up, 30 (24.0%) T2DM patients and 10 (13.0%) RA patients 
had experienced a new CV event since baseline (p=0.09) (Table 2).   
  
3.10 Discussion  
CIMT measurement by B-mode ultrasound is a valid biomarker for CV risk 
in RA and T2D patients. In the present study we demonstrated that the rate 
of CIMT progression was significantly lower in RA than T2D patients, 
despite an observation time twice as long in RA patients. At baseline, CIMT 
measurements were similar in each group. Despite a shorter follow-up 
period, a significantly greater percentage of T2D patients had CIMT 
progression than RA patients. By logistic regression, where the outcome 
was CIMT progression compared to unchanged or reduced CIMT, OR for 
progression in T2D relative to RA was 11.4. We found diabetes and ever 
use of statins but not baseline CIMT were significantly associated with 
yearly rate of CIMT change. In the RA cohort, DMARD use at baseline was 
associated with significantly lower CIMT values at follow-up.  
  
3.10.1 Differences in CV risk factors in RA and T2D  
In our study RA patients were compared to T2D patients obtained from an 
exercise prevention study [211].  Our RA and T2D cohorts were non-
matched, and the CV risk factor distribution was significantly different.  
However, the sensitivity analysis for CIMT at follow-up showed  that the 
FRS was not significant, which fits well with our models where no CVD 
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risk factors significantly impacted follow-up CIMT or CIMT progression. 
Thus, regardless of how CVD risk factors other than diabetes were 
modelled, they did not significantly influence CIMT progression. To 
account for the age and gender differences, a sensitivity analysis was 
undertaken where we compared data from 75 pairs of RA and T2DM 
matched for age and gender. This did not alter the finding that CIMT 
progression was higher in T2D than RA patients. It therefore seems unlikely 
that the mentioned differences in risk factors, age or gender have biased our 
findings.    
 
Although no CVD risk factors significantly impacted follow-up CIMT or 
CIMT progression in multivariate models, we found that CIMT progression 
in T2D was associated with use of statins. Although this may seem counter-
intuitive, statins are generally prescribed early in treatment of T2D 
according to local guidelines [216], and thus statin use is likely reflective of 
the hyperlipidaemia risk in T2D and perceived higher CV risk in RA 
patients [217]. Figure 2 illustrates that the relationship between CITM 
progression and statin use is similar in RA and T2D patients.   
 
At follow-up, 13% of RA patients had had a CV event compared to 24% of 
T2D patients (p=0.09). Although this was not a statistically significant 
difference, the current study may have been underpowered to detect 
differences in CV events, given their low frequency.  
  
3.10.2 Comparison of CIMT in RA and T2D patients  
A higher follow-up CIMT was positively associated with higher baseline 
CIMT as expected. The impact of the higher baseline on follow-up CIMT 
was eliminated by alternatively modelling CIMT yearly rate of change.   
A previous study found that yearly rate of change was higher in the first 6 
years after RA diagnosis [218]. Our failure to find a significant effect of 
disease duration may relate to a higher proportion of longstanding RA 
patients in the current than the previous study. By logistic regression of all 
patients in our study, progression of CIMT was associated with diabetes and 
ever use of a statin. While the same previous study found that in RA patients 
with disease duration of 6yrs or longer, the change in yearly CIMT of 
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patients on a statin was comparable to those of similar disease duration and 
not on a statin, the statin effect in the current study is likely to arise from the 
diabetes group and not from RA duration.  
   
3.10.3 Effect of anti-rheumatic drugs on atherosclerosis progression  
 Almost all studies exploring CIMT in RA have reported progression in 
CIMT, however some studies have found RA patients using TNF inhibitors 
have a reduction or no progression in CIMT [218-221]. In the present study 
we did not have sufficient numbers of patients (n=5) on a TNF inhibitor to 
assess the impact of TNF inhibition on CIMT progression [218]. However 
we found CIMT progression was reduced with DMARD treatment at 
baseline.  Previous studies have shown that the use of DMARDs can 
improve CV risk in RA patients by influencing traditional risk factors of 
atherosclerosis directly or through controlling inflammation [222-224]. 
Furthermore the DMARD hydroxchloroquine has shown cardio-protective 
properties by reducing LDL and increasing HDL cholesterol levels [225].   
Prednisone use in our study had no significant effect on CIMT progression, 
although in other larger studies it is suggested that glucocorticoid use may 
promote atherosclerosis [226, 227]. A recent study found an association 
between glucocorticoid use and carotid plaque in patients with systemic 
lupus erythematosus (SLE) [228]. In RA, the glucocorticoid dose is not 
normally as high as in SLE and it is possible that lower doses of 
glucocorticoids either have an anti-atherogenic effect, given the 
inflammatory nature of atherosclerosis, or have no effect on CIMT [229]. 
CIMT and carotid plaques have been found to be predictors of future CV 
events in RA, with a 2.5 increased risk of CV complications among 
unilateral plaques and 4.3 among those with bilateral plaques [230].   
 
3.10.4 Advantages of CIMT as a measure of CVD  
In 2010, EULAR published 10 key recommendations regarding CV risk 
screening and management in RA. Early detection of CV risk factors and 
annual CV risk assessment using national guidelines was recommended 
[231]. CV risk screening and management are based on CV risk score 
calculators like FRS or the systemic coronary risk evaluation (SCORE) 
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[171]. However a recent study found that carotid ultrasonography was more 
sensitive than SCORE for the detection of subclinical atherosclerosis in RA 
[232].  
 
The ASE defines CIMT as the combined thickness of the intima and medial 
layers of the far interior wall of the carotid artery [213]. ASE has set 
guidelines for measuring CIMT and states that carotid ultrasound imaging 
should follow a scanning and reporting protocol, similar to that of the 
Atherosclerosis Risk in Communities Study [233]. Of importance, both 
cohorts were examined at the same centre using the same techniques in this 
study, showing good reproducibility of CIMT measurements.  
 
A recent study supports the use of CIMT in the assessment of CV risk in 
patients with RA [234]. However, another study measuring internal carotid 
artery (ICA) IMT found an association of CVD risk with rate of change in 
ICA-IMT but not common carotid artery (CCA) IMT in RA, suggesting a 
need to evaluate both carotid arteries [218]. The standard procedure of 
measuring CIMT at this hospital is at the CCA because of its size, 
superficial location, ease of accessibility and limited movement when 
identifying subclinical vascular disease and evaluating CVD risk [213]. We 
did not examine plaque in this study.   
 
3.11 Limitations  
This study was exploratory and the sample size was small, and thus further 
studies are needed to determine the generalisability of our findings. 
Nevertheless, a large effect of diabetes was observed despite this limitation. 
Our study groups were not matched for CV risk factors. This is not possible 
when comparing RA to diabetes, because diabetes is an independent risk 
factor for CVD. However, RA patients are more likely to smoke, to be older 
and to be female. Thus, without a very large sample it would be very 
difficult to match all subjects for CV risk except RA. The advantages of our 
study are that the groups were recruited from the same hospital. They are 
from the same geographical area, similar financial background and have 
experienced being at a specialist outpatient clinic at this hospital. All CIMT 
measurement for both groups was completed by the same sonographers. We 
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were able to match 75 RA patients by age and gender to the T2DM and the 
findings using linear and logistic regression modelling were very similar to 
those reported above for the complete study cohort (data not shown).   
  
3.12 Conclusion:   
In conclusion, our data suggest that the risk of CIMT progression and CV 
events in RA patients is lower than in T2DM patients when comparing 
patients with similar baseline CIMT. A higher burden of CV risk factors in 
T2D (including diabetes itself) and early use of DMARDs in RA may 
contribute to risk reduction in RA. Future studies in larger cohorts, and 
comparing ICA-IMT and carotid plaque in RA and T2D would be of 
interest.  
  
    
Table 3-1: Characteristics of individuals with Rheumatoid Arthritis (n=78) and individuals with T2DM (n=212)  
 
Characteristics  Rheumatoid  T2DM (212)  P-value  Rheumatoid  T2DM (212)  P-value  
 Arthritis  Baseline  Arthritis Follow  Follow-up  
 Baseline (78)  up (78)  
 
Age, (yrs)   61 (10)  55 (10)  0.001  66 (10)  58 (10)  0.001  
Sex, (female)   52 (67%)  98 (46%)  0.002        
Interval between  
CIMT measurements  
       
4.8 (0.85)  
 
2.4 (1.0)  
 
0.001  
Disease Duration  13.7 (4.5-23)  4.0 (1.0-10.0)    19.1 (9.9-28)  6.4 (3.4-12.4)  0.0005  
Ever Smoker  53.0 (68%)  94.0 (44%)  0.001  57.0 (73%)  NA    
Hypertension   27.0 (35%)  100.0 (47%)  0.056  39.0 (51%)  64.0 (30%)  0.001  
Hypercholesterolemia  35.0 (47%)  121.0 (58%)  0.094  27.0 (35%)  NA    
CV events ∞   13 (16.7%)  0  0.001  10 (13.7%)*   30 (24.0%)  0.09  
Statins (mg)  15.0 (19%)  83.0 (39%)  0.001  24.0 (31%)  71.0 (34%)  0.66  
Weight (kg)  75 (17.0)  92 (19.0)  0.001  76 (17.0)  92 (19.0)  0.001  
BMI (kg/m2)   27 (6.0)  32 (6.0)  0.001  28 (8.0)  32 (6.0)  0.001  
Systolic blood 
pressure (mmHg)   
 
132 (19.0)  
 
130 (19.0)  
 
0.44  
 
126 (13.0)  
 
139 (18.0)  
 
0.001  
                                                 
2 Inter-quartile ranges, T2DM=type 2 diabetes mellitus, NA=not available, ∞ myocardial infarction, angina, stroke  
*New CV events exclusive of baseline CV events  
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Diastolic blood 
pressure (mmHg)   
 
79 (9.0)  
 
82 (9.0)  
 
0.039  
 
77 (8.0)  
 
80 (10.0)  
 
0.016  
Serum cholesterol 
(mmol/L)   
 
4.73 (1.62)  
 
4.85 (1.03)  
 
0.61  
 
4.13 (1.77)  
 
4.60 (1.00)  
 
0.36  
HDL cholesterol 
(mmol/L)   
 
1.5 (0.42)  
 
1.35 (0.40)  
 
0.003  
 
1.44(0.81)  
 
1.22 (0.40)  
 
0.013  
Serum triglycerides 
(mmol/L)2  
 
1.10 (0.90-1.50)  1.50 (1.10-2.20)  
 
0.001  
 
1.0 (0.80-1.50)  1.45 (1.10-2.10)  
 
0.001  
LDL Cholesterol 
(mmol/L)  
3.00(1.0)  2.70 (0.90)  0.063  2.84 (0.90)  2.60 (0.90)  0.019  
 
HbA1c2  
 
n/a  
7.20 (6.50-8.30)  
   
n/a  
7.60 (6.80-8.60)  
  
 
Table 3-2: Characteristics of RA patients (n=78) at baseline and follow up and data on CV events in RA and T2DM  
  RA baseline (78)  T2D at   P-Value  RA at Follow-up  T2D at   P-value 
 baseline  (78)  follow up    
 (212)  (126)  
 
Early RA  19.0 (24%)            
RA duration  14.7  (12.0)  
(yrs)  
    19.0 (12.0)    0.000  
    RF  43 (58%)  
Positive  
    47 (68%)    0.44  
    ACCP    47 (68%)  
Positive  
    48 (71%)    0.82  
   SE alleles  12 (43%)            
     CRP2  7.5 (4.0-13.0)      6.0 (3.0-14.0)    0.37  
     ESR2  20.0 (10.0-37.0)      17.0 (12.0-26.0)    0.24  
Treatment              
Prednisone  34 (44%)      25 (33%)    0.088  
DMARDs~   64 (82%)      65 (83%)    <0.001  
Biologic  3.0 (3.8%)  
DMARD†   
    6 (7.7%)    <0.001  
CV Events              
Diabetes  7 (9.0%)      8 (10.0%)    <0.001  
Angina   9 (11.5%)  0  <0.001  7 (9.0%)π  10 (4.7%)  0.83  
Myocardial  9 (11.5%)  
Infarction   
0  <0.001  3 (4.1%)σ  14 (6.6%)  0.49  
Stroke   0  0    3 (3.8%)  13 (6.1%)  0.45  
 
ACCP=anti-cyclic citrullinated protein, CRP=C-reactive protein, ESR=erythrocyte sedimentation rate, 2 Inter-quartile 
ranges, ~ever use of 1 or combination of disease modifying anti-rheumatic drug, †ever use of a biologic DMARD.  
T2DM=Type2 diabetes mellitus, π analysis excluded 1 pt that had angina at baseline and follow-up, σ analysis excluded 
5 patients that had MI at baseline and follow up. Some patients had more than one type of CV event.  
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Figure 3-1: Relationship between mean CIMT at follow up and baseline in T2DM and 
RA 
• Solid black line – Relationship between mean CIMT at follow up and baseline in 
T2DM 
•  Broken Line – Relationship between mean CIMT at follow up and baseline in RA. 
• The model was adjusted for sex, ever use of statin, smoking, and baseline triglycerides, 
total cholesterol/HDL cholesterol ratio, body mass index and hypertension. 
• For the figure, age was set at the median, i.e. 57 years. Data were back-transformed to 
the original scale. 
• Thin broken lines give 95 % confidence intervals). 
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Figure 3-2: Yearly rate of change in carotid intima-media thickness in diabetes and 
rheumatoid arthritis patients 
  
1: Diabetes patients, no statin use, 2: Diabetes patients, ever statin users, 3: Rheumatoid 
arthritis patients, no statin users, 4: Rheumatoid arthritis patients, ever statin users.  
Differences between diabetes and RA patients: p<0.001. Differences within diabetes and 
RA diagnosis group: p=0.12 and p=0.82, respectively.   
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Figure 3-3: Carotid intima-media thickness at follow-up depending on DMARD treatment.  
Relationship between mean CIMT at follow-up and baseline for patients without DMARD 
(disease-modifying anti- rheumatic drug) treatment at baseline (solid line) and patients with 
DMARD treatment at baseline (broken line). The model was adjusted for ever use of statin, 
ever use of prednisone and smoking. For the figure, age was set at the median, i.e. 62 years. 
Data were back-transformed to the original scale. Thin broken lines give 95 % confidence 
intervals. Overlap of confidence intervals cannot be used to assess significance in the 
multivariate model.  
 
Transition to Chapter 4 
 
Infectious diseases (e.g. HIV), neurological disorders (e.g. AD, HD and 
ALS), affective disorders (e.g. schizophrenia, depression and anxiety), 
autoimmune diseases (e.g. MS and rheumatoid arthritis), peripheral 
conditions (e.g. cardiovascular disease) and malignancy (e.g. 
haematological neoplasia and colorectal cancer) are reported to be 
associated with the up-regulation of the kynurenine pathway. Indoleamine 
2,3 dioxygenase is the first enzyme along the kynurenine pathway, and is 
strongly stimulated by inflammatory molecules. The final chapter we 
analysed serum KYN from a cohort of RA patients in a 10 year follow-up 
study. 
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Chapter 4: Kynurenine and tryptophan 
concentrations and kynurenine/tryptophan ratio in 
rheumatoid arthritis patients: A 10year follow-up 
study.   
  
4.1  Background  
Indoleamine 2,3 dioxygenase catalyzes the rate-limiting step of tryptophan 
degradation along the kynurenine pathway.  The depletion of tryptophan and 
generation of kynurenines play a modulatory role in the immune response. 
An increase in indoleamine 2,3 dioxygenase activity  determined by 
tryptophan / kynurenine ratio has been shown to be associated with 
infectious diseases (e.g. AIDs), neurological disorders (e.g. amyotrophic 
lateral sclerosis), affective disorders (e.g. depression, anxiety), autoimmune 
disease (e.g. multiple sclerosis, rheumatoid arthritis), peripheral conditions 
(e.g. cardiovascular disease) and malignancy (e.g. hematological neoplasias 
and colorectal cancer).   
 
Aim  
To measure serum kynurenine in baseline samples from a rheumatoid 
arthritis cohort with 10 year follow-up for cardiovascular events, and to 
investigate the relationship between kynurenine concentrations, malignancy, 
infection, cardiovascular disease, cause of death and disease activity in RA. 
 
Methods  
Baseline sera from 129 rheumatoid arthritis patients were analysed in 2013. 
These 129 patients derived from an original cohort of 231 rheumatoid 
arthritis patients recruited and followed since 2003 (baseline). Medical 
records of the 231 patients were reviewed in 2013 to determine 
cardiovascular risk factors, new cardiovascular events, duration of 
rheumatoid arthritis and rheumatological medications between 2003 and 
2013. An additional 32 healthy control sera were collected in 2003. 
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Kynurenine and tryptophan concentration levels were measured in patient 
and control sera by high performance liquid chromatography (HPLC). 
 
Results  
Kynurenine concentrations at baseline were higher in the RA patients than 
the healthy controls. Serum kynurenine concentrations were not related to 
features of rheumatoid arthritis severity, or associated with baseline and 
previous cardiovascular disease, new cardiovascular disease during follow-
up, or the two combined. Furthermore there was no association between 
kynurenine and malignancies or death.  The only variable associated with 
death was pack-years smoking.  
 
Conclusion  
Although serum kynurenine concentrations are significantly higher in RA 
than in healthy controls, they were not associated with CVD, new 
malignancies or death.  
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4.2  Introduction  
It is now well recognized that patients with rheumatoid arthritis (RA) have 
increased morbidity and mortality due to premature cardiovascular (CV) 
disease (CVD). There is a 1.5-fold increase in the standardized mortality 
ratio due to CV events in RA patients compared with the general population 
[235]. Up to 50% of this excess CV mortality results from ischemic heart 
disease (IHD), and this is closely followed by cerebrovascular disease [102, 
236, 237]. Immune dysregulation and systemic inflammation are believed to 
be integral to the development of accelerated atherogenesis in RA patients 
[198, 238, 239].   
 
Under normal conditions, regulatory T-cells (Treg) suppress immune 
activation including self-antigen-driven inflammation, thus inhibiting 
autoimmunity. Some but not all studies indicate that Treg function is 
impaired in RA, possibly due to the high concentrations of the pro-
inflammatory cytokine tumour-necrosis factor (TNF) [240]. Patients with 
RA have increased numbers of pro-inflammatory Th17 cells [241, 242]. 
Some studies have shown reduced and others increased numbers of Treg 
cells in RA [243]. There is also evidence that Treg may develop into Th17 
cells in autoimmune arthritis [244], also supporting the concept of immune 
dysregulation in RA.   
 
Atherosclerosis is the result of chronic inflammation in the arterial walls. 
Treg have been shown to inhibit atherosclerosis by affecting lipoprotein 
metabolism. Depletion of Treg in mice led to a more atherogenic lipoprotein 
profile and increased atherogenesis [245]. Thus, Treg impairment in RA 
patients may be one mechanism underlying accelerated atherosclerosis.   
Kynurenine (KYN), a breakdown product of the amino acid tryptophan 
(TRP), has emerged as a molecule with immunomodulatory effects [246]. 
Three different enzymes catalyse the formation of KYN from TRP: 
Indoleamine 2,3-dioxygenases (IDO) 1 and 2 and TRP 2,3-dioxygenase 
(TDO). IDO1 can be found in macrophages, microglia, neurons and 
astrocytes [143, 144, 247]. IDO1 is upregulated by certain cytokines and 
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inflammatory molecules, particularly interferon gamma (IFN- ) [247, 248]. 
Indoleamine 2,3 dioxygenase 2 (IDO2) is a recently-discovered enzyme and 
its encoding genes are located next to IDO1 . IDO2 possess similar structure 
and enzymatic activities to IDO1, but differs in its expression pattern and 
signalling, and is preferentially inhibited by D-1methyl-TRP [139, 140]. 
TDO resides primarily in the liver and is induced by TRP or corticosteroids 
[141].  Several cytokines, including TNF, activate IDO to promote KYN 
formation. Through several pathways, KYN and its metabolites induce 
apoptosis of CD4+ Th1 T-cells and generation of Tregs, thereby regulating 
T-cell responses. A recent study demonstrated that development of 
collagen-induced arthritis was associated with increased IDO activity and 
enhanced tryptophan catabolism in mice. Blocking IDO with its inhibitor, 1-
Methyl-Tryptophan, aggravated the severity of arthritis and enhanced 
immune responses. These findings suggest that IDO may play an important 
and novel role in the negative feedback of collagen-induced arthritis and 
possibly in the pathogenesis of rheumatoid arthritis [250].   
 
In patients undergoing coronary angiography for suspected coronary artery 
disease, an increased KYN/TRP ratio in urine was strongly associated with 
major coronary events, acute myocardial infarctions, ischemic stroke, and 
all-cause mortality [149]. Similarly, an increased ratio was linked with more 
advanced atherosclerotic changes in patients on chronic haemodialysis due 
to kidney failure [150].  In these settings, KYN may be acting as a 
biomarker of inflammation. Taken together, these studies suggest that KYN 
may play various roles in the interactions between inflammation, immune 
dysregulation, CVD risk and possibly the risks of cancer and infections in 
RA patients. Here we hypothesized that increased serum KYN in RA 
patients is associated with risk of CVD, cancer, serious infections and 
increased severity of RA. Therefore our aim was to investigate the 
relationship between kynurenine concentrations, malignancy, infection, 
CVD, cause of death and disease activity in RA.  
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4.3 Materials and methods:  
4.3.1 Study Population  
We recruited two hundred and thirty one RA patients who met the American 
College of Rheumatology (ACR) 1987 revised criteria for the classification 
of RA and presented for a scheduled appointment over a 5-month period 
(July to November 2003) at a tertiary hospital rheumatology clinic. This 
cohort has been previously described [251]. This cohort was followed for 10 
years within this hospital clinic setting. Thirty two adult healthy controls 
were recruited from another study and from laboratory staff from whom 
written consent was obtained.  
  
4.3.2 Baseline data:   
At baseline, CV risk factors and events were collected by completion of a 
self-administered questionnaire detailing CV history, risk factors, treatment, 
and details of RA, as well as laboratory data. Each patient was clinically 
evaluated, with chart review to confirm history. The data on high density 
lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), 
triglycerides, systolic and diastolic blood pressure, weight,  body mass index 
(BMI), smoking and previous cardiovascular disease (CVD) were recorded 
and previously described [251]. The percentage risk of CV events over the 
next 5 years was estimated using the 'CV disease risk calculator' derived 
from the Framingham study [251]. Serum was available from 129 patients at 
baseline, of whom 16 had died. No clinical data were available from the 
healthy controls.  
  
4.3.3 10-year follow-up data:  
At follow-up, hospital records of all 231 participants were reviewed to 
determine new cardiovascular disease events, death, malignancy and 
infection information over last 10 years.  
Thirty one participants died during follow-up.   
  
4.4 Measurement of Kynurenine  
Blood samples were collected at baseline and aliquots of serum were stored 
at - 80⁰C until analysis. Serum concentrations of KYN and TRP were 
analyzed by high performance liquid chromatography as described [4]. 
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Briefly 50 µl of serum were diluted with 50 µl of normal saline and then 10 
µl of 150mM sodium acetate buffer pH 4.0 was added and left at room 
temperature for 2 minutes. 27 µl (1/4 volume) of 30% TCA was added and 
mixed immediately with vortex. Sample mixtures were incubated on ice for 
5 minutes before spinning on the pre-cooled microfuge (4℃) with max 
speed (14,000 rpm). After spinning, supernatants were used for 
chromatography. Standards were prepared with both low (1 µM and 0.1 
µM) and high (100 µM and 10 µM) concentration of TRP and KYN. KYN 
and TRP were detected with UV detector at 360 nm and 285 nm excitation 
respectively. The ratio of KYN/TRP concentrations was calculated.  
This study was approved by Metro South Human Research Ethics 
Committee and the Australian Health & Welfare, National Death Index 
registry Human Research Ethics Committee.  
  
4.5 Statistical Analysis:   
For analysis, we used SPSS and Stata (version 13.0), and the “party” 
program in R. Categorical data are presented as number and percentages and 
chi square tests were used to compare baseline and follow-up frequencies. 
Continuous data are presented as mean and standard deviation or median 
and inter-quartile range (IQR) or 95% confidence intervals as indicated. T-
tests or Mann-Whitney U-tests were used for comparisons depending on 
data distribution. Multivariate robust linear regression was used to analyze 
RA concentrations. Transformation to normality was performed if 
necessary, and model fit was checked by residual plotting.  
 
 For analysis of dichotomous endpoints we used multivariate logistic 
regression modelling, and for analysis of death, multivariate Cox regression.  
P-values less than 0.05 were considered to indicate significant differences. 
The number of possible explanatory variables was high compared to the 
number of positive outcomes. Therefore, we first performed random forest 
analysis with bootstrapping (n=2000) for feature selection. The following 
variables were included in the random forest analysis: On the next step 
using logistic regression or survival analysis, only the variables with an 
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association to the outcome stronger than random variation in the random 
forest analysis were included [252]. 
 
Results  
The original cohort consisted of 231 RA patients [251], of whom serum 
KYN concentration levels were measured in 129. The follow-up 
characteristics of the cohort are in Table 1. At the 10 year follow-up, this 
cohort had more smokers and a higher body mass index compared to 
baseline (described previously). These patients had a higher frequency of 
angina, myocardial infarction, stroke, diabetes, new and old CV events.   
 
Table 4-1: Characteristics of RA patients  
 
 n (%) 
Females  80.0 (62.0%)  
Age (yrs)  62.0 (13.0)  
Weight  75.0 (20.0)  
Body Mass Index  28.0 (7.0)  
Current smoker  29.0 (23.0%)  
Duration of Rheumatoid Arthritis  14.0 (13.0)  
Hypertension  39.0 (30.0%)  
Hyperlipidemia  33.0 (26.0%)  
Previous Cardiovascular Disease    
   Angina  9.0 (7.0%)  
   Myocardial Infarction  8.0 (6.0%)  
   Stroke  10.0 (8.0%)  
Diabetes  16.0 (12.0%)  
New Cardiovascular  event  21.0 (16.0%)  
Old Cardiovascular  event  9.0 (7.0%)  
Old and New Cardiovascular  event  6.0 (5.0%)  
Systolic Blood Pressure  132.0 (19.0)  
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Diastolic Blood Pressure  77.0   (11.0)  
Inflammatory markers    
Erythrosedimentation Rate  26.0 (23.0)  
C-reactive Protein  20.0 (34.0)  
 
Cholesterol  
 
5.1 (1,1)  
Triglycerides*  1.3 (1.0-1.9)  
High Density Lipoprotein  1.5 (0.5)  
Low Density Lipoprotein  3.0 (0.9)  
Tryptophan  57.0 (28.0)  
Kynurenine  1.21 (0.58)  
 
Numbers (%), Mean (SD), *Median (IQR).  
  
KYN concentrations in RA patients (median 95% CI) 1.09 (0.99-1.14) µM 
were higher than in healthy controls 0.91 (0.76-1.00) µM, p=0.007 (fig 1). 
TRP concentrations in RA patients 48.5 (46.0-53.0) µM were also higher 
than in controls 42.0 (37.0-47.0) µM, p=0.024 (fig 2).  This difference was 
due to a proportion of RA patients with higher KYN levels that the upper 
limit for controls (Figure 1). The ratio for KYN/TRP did not differ between 
RA patients and controls (p = 0.52, figure 3).  
 
Figure 4-1: KYN concentrations in RA patients and healthy controls  
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Figure 4-2: TRP concentrations in RA patients and healthy controls  
    
 
Figure 4-3: KYN/TRP ratio of RA patients and controls  
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4.7 KYN concentrations in RA patients with and without the CV and 
malignancy endpoints of the study  
 
4.7.1 A) New CV event  
Of the 129 patients with baseline KYN concentrations, 21 RA patients 
experienced a new CV event in the subsequent 10 years. Baseline KYN 
concentrations did not predict future CV events: in patients with an event, 
median KYN was 1.06 (0.83-1.32) µM and in RA patients with no new 
event 1.09 (0.97-1.17) µM, p=0.91. In RA patients with previous CVD, 
median KYN was 0.99 (0.85-1.26) µM and in those without previous CVD 
1.1 (0.92-1.16) µM, p=0.72. Based on these findings, logistic regression 
analysis was not necessary – no adjustments could change the lack of 
association of KYN with previous CVD or new CV events.  
 
 
Figure 4-4: KYN concentrations in RA patients with and without a new CV event between 
2003 and 2013.  
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4.7.2 B) New Malignancy  
In the 21 RA patients with a new malignancy at follow-up, the median 
baseline KYN concentration was 1.26 (0.84-1.46) µM and in RA patients 
without a new malignancy 1.06 (0.97-1.13) µM, p=0.54.   
 
 
Figure 4-5: KYN concentrations in RA patients with and without a new malignancy 
between 2003 and 2013.  
4.7.3 C) Death  
In the 16 RA patients who died during follow-up, the median KYN 
concentration was 1.04 (0.881.15) µM and in the RA patients still alive 1.09 
(0.97-1.23) µM, p=1.00.  Two patients with a new malignancy died, and 3 
patients with a new CV event died.  
  
 
Figure 4-6: KYN concentrations in RA patients dying or alive between 2003 and 2013. 
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4.8 Causes of death for the RA patients with KYN data:   
There were too few cases for a meaningful analysis of the relationship 
between KYN and cause of death.   
 
Table 4-2: KYN concentrations at baseline by cause of death  
 
CVD  7  43.75  
Cancer  3  18.75  
Respiratory  1  6.25  
Renal Disease  1  6.25  
Diabetes  1  6.25  
Not classified yet  3  18.75  
Total  16  100  
  
 
4.8.1 Other variables (than KYN) related to death  
Random forest analysis was used to select possible baseline explanatory 
variables predicting death of the 129 patients. Only pack-years of smoking 
and average prednisone dose were selected for logistic regression; age and 
sex were included as biologically important variables (Table 3).  Average 
prednisone dose was not significant in logistic regression (p=0.17), which 
left the best model:   
 
Table 4-3: Other variables (than KYN) related to death  
Death  Odds Ratio  95%CI  P-value  
Age  1.06  1.00-1.12  0.07  
Sex  1.48  0.40-5.47  0.56  
Pack-years smoking  1.03  1.00-1.05  0.02  
 
 
Death Cause   Frequency   Percent of deaths   
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When adjusting for age and sex, pack-years of smoking significantly 
predicted death within the next 10 years with an OR of 1.03 (1.00-1.05), 
p=0.02, or a 3% increase in likelihood of death per pack-year. KYN 
concentration was included in this model, and as expected, was not 
significant (p=0.97), confirming the findings described above.   
  
 
 A Cox regression model was run using deaths as an outcome. The best 
model was very similar to the logistic regression model, in that the only risk 
factor for death was pack-years of smoking.   
 
Table 4-4: Model with death as an outcome  
Variable  Hazard Ratio  95%CI  P-value  
Age  1.05  1.00-1.11  0.07  
Sex  1.36  0.46-4.06  0.58  
Pack-years smoking  1.02  1.00-1.04  0.00  
KYN  0.99  0.37-2.64  0.98  
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4.9  Discussion    
Although KYN has been linked to poor prognosis in cancer, renal disease 
and CVD, there is little known about the relationship between disease 
activity and KYN concentration levels in patients with RA. We found KYN 
to be a more sensitive marker to distinguish RA patients from the healthy 
controls than TRP or KYN/TRP ratio. The results of this study demonstrate 
higher KYN concentrations in RA patients compared to healthy controls, 
similar to results shown in previous studies [253-255]. Like Bett et al 
(1962), we found KYN levels to be unrelated to RA disease duration or 
disease activity [256]. In an earlier study plasma TRP concentration was 
lower in RA than controls, whilst the urinary excretion of the tryptophan 
metabolites, KYN, xanthurenic acid and 3-hydroxyanthralinic was increased 
[257]. More recently, concentrations of TRP were measured in sera of RA 
patients and found to be lower than for healthy controls, whilst KYN did not 
significantly differ from controls [255].   
  
4.9.1 The relationship between KYN and CVD  
We found no significant relationship in the RA cohort between KYN and 
either presence of CVD or new CV events. Previous studies have reported 
KYN imbalances (an increase in the rate of formation or a relative decrease 
in its rate of degradation) in CVD [258, 259]. Urine KYN was found to be a 
significant predictor of major cardiovascular events, all-cause mortality and 
CVD mortality, however there was no relationship between urine KYN and 
stroke or non-CVD mortality [149]. KYN/TRP ratio has been suggested to 
provide a more reliable measure of IDO activation than the absolute 
concentrations of KYN [260]. A previous study has demonstrated that 
elevated plasma KYN/TRP ratio levels are associated with increased risk of 
major coronary events (MCEs) and mortality in patients with stable CAD, 
participating in the Bergen Coronary Angiography Cohort (BECAC) [261]. 
These studies are substantially larger than our study, which may explain the 
difference in our results in that our study is underpowered.   
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4.9.2 Malignancy and KYN  
There were higher levels of KYN observed in patients diagnosed with colon 
carcinoma, adenoma tubule villosum, or tubular adenoma than in those from 
the control group in a recent study. [262]. In another study, KYN/TRYP 
ratio but not KYN were increased in colorectal cancer patients (n=66) 
compared to non-cancer controls (n=37) [263].   
  
4.9.3 Previous studies of predictors of mortality in RA.  
Mortality is higher in RA patients when compared to the general population, 
this excess in mortality is predominantly due to coronary artery disease, 
cerebrovascular atherosclerosis and other cardiovascular complications 
including heart failure [264] [265, 266]. CVD associated mortality risk is 
increased in both men and women who are seropositive RA [43]. CVD 
associated death could be as much as 50% higher in RA patients compared 
to controls, with the risk of ischemic heart disease and cerebrovascular 
disease increased to a similar degree [235]. The enhanced vascular risk is 
not restricted to individuals with established RA, because increased 
mortality in patients  who are positive for the RF and have early 
inflammatory polyarthritis has been reported [43, 76].  
 
We found in a population health survey that CV risk is increased pre onset 
of RA. RF-positivity early in RA is a strong predictor of mortality. This was 
demonstrated in an inception cohort of 130 RA patients, where RF-positive 
RA was associated with a 6-fold increased risk of mortality compared to 
patients who were RF negative at baseline [267]. In another study, RF-
positive patients excess mortality was found to be due to respiratory and 
cardiovascular diseases [268]. Chronic obstructive pulmonary disease was 
the most common cause of respiratory death in the RF-positive patients. 
Compared to the general population the RF-positive group had a 3-fold 
increased mortality rate [Standard Mortality Rate (SMR) 3.36 (95% CI 2.02, 
5.24)]. SMR for ischemic heart disease (IHD) including myocardial 
infarction were elevated [SMR 1.41 (95% CI 1.04, 1.88)] for RF-positive 
patients, but not in those who were persistently RF-negative [268].  
 
 79  
It is well documented that smoking is a risk factor for RF-positive RA [26, 
269]. In Finland they found through a questionnaire that people who were 
RF-positive and had arthritis, had increased mortality from all causes [270]. 
After adjusting for age, gender and smoking status the increased mortality 
risk persisted. They also found that people who were RF-positive in the 
absence of arthritis had increased cardiovascular mortality, which remained 
significant after adjusting for age, gender and smoking status.  
  
4.10 KYN concentration level and mortality  
In the present study there were no differences in KYN at baseline between 
the 16 patients who died during follow-up or the patients that survived and 
there were too few cases for a meaningful analysis of KYN and cause of 
death.  In logistic regression and Cox regression analysis, after adjusting for 
age and sex, pack-years of smoking was the only significant predictor of 
death in our cohort. A recent study “Epidemiology and Cost-effectiveness of 
Out-Of-Hospital Cardiac Arrest in Finland (FINNRESUSCI)” found KYN 
correlated with intensive care unit death, that KYN was significantly higher 
in patients who died compared to those that survived, and that KYN was 
higher in patients with poor outcomes compared with those with good 
outcomes [271]. Even though this cohort had twice the sample size (n=245) 
of our own RA cohort, it is unlikely that doubling the size of the RA cohort 
would have been able to show a relationship between KYN and mortality 
based on the small differences observed here.   
  
4.11 Limitations  
The major limitation of this study is the small sample size and very few 
endpoints. Based on our data, one would require a very large study to get 
enough statistical power to demonstrate an association between KYN and 
RA complications.  In the healthy controls, no clinical characteristics were 
available. Thus we could not compare them further to the RA cohort. There 
was a high probability that the healthy controls were much younger than the 
RA patients.  In the present study KYN in serum has a very narrow 
concentration range, therefore this test has low capacity for questions of 
prediction.  
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4.12 Conclusion  
Median KYN concentrations were significantly higher in RA patients than 
in healthy controls, but there was a large overlap between groups. There 
were no variables in our data set that could explain the differences in KYN 
concentrations among the RA patients. KYN concentrations were not 
related to previous or new CVD, new malignancies or death. The only 
variable predicting death in our 10 year follow-up of 129 RA patients in 
logistic or Cox regression was pack-years of smoking.   
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Chapter 5: Final Discussion  
Most of the work presented in this thesis has already been discussed in the 
individual chapters (2, 3 and 4). The main aim of this chapter is to 
cohesively bring all the findings together to highlight an overall conclusion 
of the thesis, the impact of the findings and how they may lead to future 
research.  
 
In this thesis, I report that CVD and CVD risk factors are significant 
predictors of RA, that the increase in CIMT is similar in patients with RA 
and T2D, and that KYN concentration levels are elevated in a subset of RA 
patients compared to healthy controls but are not associated with risk of 
death or CVD. 
 
The most important pathophysiologic mechanism of CV risk in RA is the 
relationship between systemic inflammation and atherosclerosis. There is 
substantial evidence that there are influences beyond traditional risk factors 
that link RA and CVD and this has led to the notion that RA patients carry 
additional risk factors for CVD. I propose that inflammation and disease 
activity are the fundamental links for the 3 studies.  
 
In chapter 2 I reported an association of previous CV events with the 
development of RA in individuals exposed to common RA and CV risk 
factors. The increase in CVD and CV risk factors also occurs in patients 
with established RA and at those at disease onset. My results concur with 
previous studies showing that female gender, increasing age, increasing 
BMI and smoking were risk factors for incident RA. The obvious caveat of 
this study is we have relied mainly on self-reported information to detect the 
presence of RA. The positive predictive value of self-reported RA has been 
studied in various populations including the elderly and disabled, and was 
found to be low, ranging between 21% and 34%. (3).  
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It is well documented that patients with RA and T2D develop more CV 
events than the general population, as reflected in CIMT measurements. 
However it is not clear how rapidly CVD progresses in RA relative to T2D, 
which has a similar increased CV risk. We demonstrated (chapter 3) that 
RA patients had similar baseline CIMT to T2D patients. Previous studies 
have shown that DMARDs can improve CV risk in RA patients, by 
influencing traditional risk factors of atherosclerosis directly or by 
controlling inflammation. In our RA cohort we reported that DMARD use at 
baseline was associated with significantly lower CIMT values at follow-up 
than in the T2D group at follow-up. The limitations for this study are 1. The 
small sample size, and 2. The cohorts were not fully matched. In a 
sensitivity analysis however, we were able to match 75 pairs and the results 
were similar. 
 
Previous studies have found that the enzyme KYN correlated with intensive 
care unit death, and that KYN was significantly higher in patients who died 
compared to those that survived. Furthermore, KYN was higher in patients 
with poor outcomes compared with those with good outcomes (4). We did 
not find similar results in our cohort of RA patients. We did not undertake a 
preliminary power calculation, as the study was exploratory. However, the 
effect size of elevated KYN was small and we determined that we would 
require a very large study to get enough statistical power to demonstrate an 
association between KYN and RA complications.  In the healthy controls, 
no clinical characteristics were available, thus we could not compare them 
further to the RA cohort. There was a high probability that the healthy 
controls were much younger than the RA patients.  In the present study 
KYN in serum has a very narrow concentration range, therefore this test has 
low capacity for questions of prediction.  
 
Future research 
Further studies addressing predictors for cardiovascular disease are needed. 
When evaluating the extent of CV risk in RA, identifying markers of 
inflammation and disease activity might be useful. Given that previous CV 
events were associated with the development of RA, future studies should 
focus on the development of effective screening methods to identify patients 
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with high cardiovascular risk and who would benefit from close monitoring 
for early signs of RA requiring intervention, as well as management of CV 
risk factors. There should be clear guidelines for the management of CV risk 
factors in RA, similar to guidelines developed for diabetes. 
 
From the data presented, it is unlikely that CIMT is a useful outcome 
measurement for following CVD in longitudinal studies in RA. Further 
outcome studies comparing CV events in RA and T2D patients would be 
more useful. However these would need to be of long duration and large 
size.  
 
Taken all together, these results emphasize the complexity of the 
associations between inflammation, anti-rheumatic therapies, atherosclerotic 
burden and CVD in RA.  
The main contributions to the field of RA and CVD research within this 
thesis were  
• Demonstrating that CVD precedes the onset of RA   
• Comparing CIMT in T2D and RA; T2D has a higher CIMT progression 
compared to RA  
• Measuring KYN concentrations in RA found levels were higher for RA 
than for healthy controls.  
 
To effectively prevent cardiovascular events in patients with RA, we must 
identify RA disease characteristics which signal an increased risk of CVD. 
Identification of patients at high risk will support an effective individualized 
strategy of targeted therapy. Our studies indicate that patients with active 
RA disease qualify for intensified action in order to prevent future CV 
events.  
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http://arthritis-research.com/content/16/2/R85RESEARCH ARTICLE Open AccessCardiovascular disease is increased prior to onset
of rheumatoid arthritis but not osteoarthritis: the
population-based Nord-Trøndelag health study
(HUNT)
Helen Pahau1, Matthew A Brown1, Sanjoy Paul2,5†, Ranjeny Thomas1*† and Vibeke Videm3,4†Abstract
Introduction: Patients with rheumatoid arthritis (RA) have increased risk of cardiovascular (CV) events. We sought
to test the hypothesis that due to increased inflammation, CV disease and risk factors are associated with increased
risk of future RA development.
Methods: The population-based Nord-Trøndelag health surveys (HUNT) were conducted among the entire adult
population of Nord-Trøndelag, Norway. All inhabitants 20 years or older were invited, and information was collected
through comprehensive questionnaires, a clinical examination, and blood samples. In a cohort design, data from
HUNT2 (1995–1997, baseline) and HUNT3 (2006–2008, follow-up) were obtained to study participants with RA
(n = 786) or osteoarthritis (n = 3,586) at HUNT3 alone, in comparison with individuals without RA or osteoarthritis at
both times (n = 33,567).
Results: Female gender, age, smoking, body mass index, and history of previous CV disease were associated with
self-reported incident RA (previous CV disease: odds ratio 1.52 (95% confidence interval 1.11-2.07). The findings
regarding previous CV disease were confirmed in sensitivity analyses excluding participants with psoriasis (odds ratio
(OR) 1.70 (1.23-2.36)) or restricting the analysis to cases with a hospital diagnosis of RA (OR 1.90 (1.10-3.27)) or
carriers of the shared epitope (OR 1.76 (1.13-2.74)). History of previous CV disease was not associated with increased
risk of osteoarthritis (OR 1.04 (0.86-1.27)).
Conclusion: A history of previous CV disease was associated with increased risk of incident RA but not
osteoarthritis.Introduction
Rheumatoid arthritis (RA) is a systemic, inflammatory
autoimmune disorder that primarily involves the joints.
Despite treatment advances, RA patients continue to
have higher mortality and morbidity rates than the
general population, predominantly related to increased
atherosclerotic cardiovascular (CV) disease [1,2]. The
traditional CV risk factors include age, gender, family
history, smoking, diabetes, hypertension, dyslipidemia,
obesity and sedentary lifestyle. RA patients carry a* Correspondence: ranjeny.thomas@uq.edu.au
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unless otherwise stated.higher burden of some of these factors. The disease oc-
curs most commonly after 40 years of age and is associ-
ated with accelerated cellular ageing [3]. A history of
smoking is associated both with RA development and
severity [4-6]. Physical inactivity is common in patients
with RA and may increase co-morbidity due to obesity
or diabetes, leading to an increased risk of CV mortality
[7]. Some studies have also suggested that myocardial
disease without atherosclerosis is more prominent in RA
patients. For example, an echocardiography study dem-
onstrated that RA patients asymptomatic for CV disease
had ischemia more frequently than controls, but they
also had fewer significant angiographic coronary artery
stenoses [8]. Likewise, an autopsy study showed that RA
patients had diffuse myocardial fibrosis or non-specifictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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after excluding individuals with other known causes [9].
Inflammation plays a central role in the pathogenesis
of atherosclerosis, and the increase in CV disease and
mortality in RA may partly be explained by inflamma-
tory factors associated with RA, even after adjustment
for traditional CV risk factors [10,11]. We and others
showed that atherosclerosis is increased both in patients
with established RA and at presentation in patients with
recent-onset RA, as determined by increased carotid in-
tima media thickness and plaque, and is associated with
their inflammatory burden [12,13]. The risk for myocar-
dial infarction (MI) and possible CV death is already in-
creased within approximately 5 years after diagnosis of
RA depending upon age and presence of CV risk factors,
resulting in a 10-year absolute risk comparable to non-
RA individuals who were 5 to 10 years older [14].
It has been demonstrated that inflammation pre-dates
the onset of RA [15]. These data suggest that an in-
creased risk of CV disease might also precede the onset
of RA. The Rochester Epidemiology Project study dem-
onstrated that RA patients were more likely to have been
hospitalized because of MI prior to RA diagnosis [16].
However, a previous longitudinal cohort study found no
difference in the rate of MI, congestive heart failure or
angina between pre-RA and control individuals [17].
We hypothesized that CV risk factors and events are
more prominent in persons with incident RA, and that
this augments the risk of future RA development by in-
creasing inflammation. The aim of the study was there-
fore to investigate the effects of CV risk factors and CV
events on the development of RA, using a population-
based cohort study design. As a control to study whether
any findings were specific to RA or related to arthritis in
general, a parallel investigation was performed in partici-
pants with and without osteoarthritis.
Methods
The study participants were from the Nord-Trøndelag
Health Study (HUNT) population-based health surveys
conducted in the county of Nord-Trøndelag in Norway.
The county is fairly representative for Norway as a whole,
with a stable and ethnically homogenous population (3%
non-Caucasians). All inhabitants 20 years or older were
invited, and information was collected through compre-
hensive questionnaires and a clinical examination. The
HUNT2 survey has previously been described in detail
[18]. The HUNT3 survey had a similar design. In total,
about 75,000 (70% of those invited) participated in
HUNT2 (1995 to 1997), 51,000 (54% of those invited) par-
ticipated in HUNT3 (2006 to 2008), and 37,071 partici-
pated in both HUNT2 and HUNT3. By design, the
participants were not seen during the years between inclu-
sion in HUNT2 and HUNT3.The study cohort consisted of all participants in both
HUNT2 and HUNT3 who answered whether they had a
diagnosis of RA or not (n = 36,493, that is, 98.4% of
37,071) and this number determined the study size. Inci-
dent cases of RA were identified, that is, participants
who reported a diagnosis of RA in HUNT3 but not in
HUNT2. We also identified the incident cases of osteo-
arthritis for comparison, based on the question: “Has a
doctor ever said that you have/have had any of these dis-
eases: degenerative joint disease (osteoarthritis)?” The
question also included the Norwegian colloquial term
for osteoarthritis. Each patient group was compared to
the remaining participants of the study cohort.
Participants of HUNT gave informed consent. Ap-
proval for the study was obtained from the Regional
Committee on Medical Research Ethics, Central Norway,
the Norwegian Data Safety Authorities and the Norwegian
Department of Health. Ethics approval was also obtained
by the Metro South Ethics Committee Brisbane. Permis-
sion was granted from the two primary hospitals in
Nord-Trøndelag, Levanger and Namsos hospitals, and the
nearest secondary referral hospital, Trondheim University
Hospital, to link the identified RA cases in our study to
the hospital diagnosis registries for verification of diag-
nosis. The registered diagnoses are used for billing and re-
imbursement from the national insurance scheme. We
searched for the ICD-9 code 714 and ICD-10 codes M05
and M06 with sub-codes. We did not have permission to
access to the patients’ case notes in order to check that the
current criteria for RA were correctly employed.
On enrolment in HUNT2 and HUNT3 the participants
completed a questionnaire incorporating information on
medical history, smoking habits and family history of CV
disease, defined as a parent, sibling or child with previous
MI or stroke. Information on the use of lipid-lowering
medications or non-steroid anti-inflammatory drugs was
not available. Anthropometric and clinical measures in-
cluded height, weight, waist and hip circumference, and
blood pressure. Non-fasting blood samples were drawn and
total cholesterol, low-density lipoprotein (LDL) cholesterol,
high density lipoprotein (HDL) cholesterol, triglycerides
and serum glucose were measured using an autoanalyzer
(Hitachi Biocore Systems, Thornhill, ON, Canada). Using
DNA isolated at HUNT Biobank, participants with self-
reported RA were genotyped for the Shared Epitope [19].
Samples were genotyped using the Illumina Immunochip
microarray chip, and HLA-DRB1 genotypes then determined
by imputation using the program HLA-IMP [20,21]. Auto-
antibodies (anti-citrullinated peptide antibodies or ACPA,
rheumatoid factor) and C-reactive protein were not mea-
sured in this survey, and classification into seropositive or
seronegative RA was not possible. Hypertension was defined
as systolic blood pressure ≥140 mmHg, diastolic blood pres-
sure ≥90 mmHg or use of medication. Hypercholesterolemia
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mass index (BMI) was calculated as weight/height2 (kg/m2).
Patients who reported using over-the-counter analgesics
daily for one month or more during the last year before
inclusion in HUNT2 were recorded as users of analgesics.
Previous CV disease was defined as a composite of angina,
MI or stroke. The relevant questions were; “Have you had
or do you have angina pectoris?” “Have you had a stroke/
brain hemorrhage?” and “Have you had a myocardial
infarction?” The question about angina also included a
Norwegian colloquial term for this diagnosis. The com-
posite variable was used for previous CV disease as num-
bers of cases were too low for analysis of individual
disease events. The level of missingness at baseline for
most key variables was <1%, with the exception of smok-
ing (12.8% missing data). Missingness for smoking was
evenly distributed among the subgroups of the study co-
hort. Non-complete cases were omitted from analysis.
Statistical methods
Data are presented as number (percentage), mean (stand-
ard deviation) or median (interquartile range), as appropri-
ate. The chi-square test and the Mann-Whitney U-test
were used for between-group comparisons of categorical
and continuous study parameters, respectively. Risk factors
associated with the development of RA and osteoarthritis
between HUNT2 and HUNT3 were identified using
multivariate logistic regression models. Linearity of logits
for continuous variables was checked by plotting.
P-values <0.05 were considered significant. Pearson’s cor-
relation coefficient R was calculated to evaluate linear
correlation.
Since this was a population-based survey and RA was
self-reported, we performed several sensitivity analyses to
support our main analysis. Because previous studies have
indicated that few women with RA surveyed in the com-
munity report their diagnosis accurately [22], we repeated
the analysis in several subgroups of the incident RA cases
using additional criteria to remove false-positive diag-
noses, that is, 1) excluding all who also reported having
psoriasis (n = 178), 2) including only patients where the
diagnostic registries of the nearest hospitals showed a
diagnosis of RA (n = 216), 3) restricting the hospital-
diagnosed cases to those where the diagnosis first oc-
curred after 1999 or 4) after 2001, to avoid including
patients who forgot to report RA in HUNT2, or 5) includ-
ing only incident RA cases who carried the shared epitope
(with and without additional exclusion due to a report of
psoriasis). To represent the CV risk factors in another
way, we developed alternative models including the
Framingham risk score, which is based on age, serum
cholesterol, hypertension, smoking and diabetes [23], as
well as gender and history of CV disease. The Framingham
risk score was preferred because it assigns higher risk withdiabetes and there are no age limits, and because it may
easily be calculated in large cohorts. The European Heart-
Score [24] is based on risk for patients between 40 and
65 years and requires separate input for each individual
using charts or an online calculator, which was not prac-
tical in our large cohort. To verify that the Framingham
risk score was applicable in our cohort, we calculated the
PC-based HeartScore for 50 randomly selected incident
RA cases and 50 controls. Parallel Framingham risk scores
and HeartScores were used to calculate an equation per-
mitting estimation of the HeartScore in the entire cohort
from their Framingham risk scores. An alternative logistic
model was developed substituting the Framingham risk
score with these estimated HeartScores. In addition,
we compared factors associated with incident cases of
self-reported RA with incident cases of self-reported
osteoarthritis.
Results
The baseline characteristics of the participants are pre-
sented in Table 1. At baseline (1995 to 1997) 33,567 par-
ticipants reported not having RA, and of this group 786
(2.34%) reported RA at follow-up (2006 to 2008). This
corresponds to an average annual incidence of 0.21% in
women and 0.16% in men, respectively. If restricted to
participants with cases identified in the local hospital
registries (n = 216), the annual incidence was 0.06% in
women and 0.04% in men. As expected, incident cases
of RA were older and more of them were current or pre-
vious smokers and had hypertension at baseline. Inci-
dent cases of RA had significantly elevated metabolic
risk factors including blood pressure, BMI, serum chol-
esterol and triglyceride. The estimated median (inter-
quartile range) Framingham risk scores at baseline were
11 (7, 16) and 8 (4, 13), respectively, in incident cases
and those who did not develop RA. Notably, a higher
proportion of incident RA cases had a history of CV dis-
ease at baseline.
Female gender, age, smoking, BMI and previous CV
disease were more prominent in those developing RA
(odds ratio 1.52 (1.11 to 2.07), Table 2, I - Main model).
There was minimal change in the odds ratio for previous
CV disease with inclusion of use of analgesics in this lo-
gistic regression model, when systolic and diastolic
blood pressure were included as continuous variables in-
stead of the categorical variable for hypertension, with
additional adjustment for total cholesterol and HDL-
cholesterol concentrations, or when a variable for phys-
ical activity (low, moderate, high) was also included (data
not shown). In all the alternative multivariate models for
incident RA where the number of patients was restricted
to better characterized subgroups, previous CV disease
was significant and the odds ratios were higher than for
the main model including all self-reported cases (Table 2,
Table 1 Characteristics of individuals without rheumatoid arthritis (RA) or osteoarthritis (OA) at baseline
All participants
without RA/OA
Later developed
RA
Did not develop
RA
P-value Later developed
OA
Did not develop
OA
P-value
n 33,567 786 32,781 3,586 29,981
Age1 (years) 46 (13) 51 (13) 46 (13) ** 52 (10) 45 (13) **
Sex (female) 18,207 (54.2%) 488 (62.1%) 17719 (54.1%) ** 2,406 (67.1%) 15,801(52.7%) **
Smoking ** **
Current 8,901 (26.5%) 256 (32.6%) 8,645 (26.4%) 1,015 (28.3%) 7,886 (26.3%)
Former smoker 7,908 (23.6%) 212 (27.0%) 7,696 (23.5%) 945 (26.4%) 6,963 (23.2%)
Never smoker 15,017 (44.7%) 281 (35.6%) 14,736 (45.0%) 1,425 (39.7%) 13,592 (45.3%)
Hypertension 12,186 (36.3%) 339 (43.1%) 11,847 (36.1%) ** 1,547 (43.1%) 10,639 (35.5%) **
Diabetes 454 (1.4%) 19 (2.4%) 435 (1.3%) * 61 (1.7%) 393 (1.3%)
Previous CV disease 1,060 (3.2%) 52 (6.6%) 1,008 (3.1%) ** 158 (4.4%) 902 (3.0%) **
Angina 673 (2.0%) 35 (4.5%) 638 (1.9%) ** 107 (3.0%) 566 (1.9%) **
MI 441 (1.3%) 16 (2.0%) 425(1.3%) 49 (1.4%) 392 (1.3%)
Stroke 223 (0.7%) 9 (1.1%) 214 (0.7%) 32 (0.9%) 191 (0.6%)
Family risk of CV disease 15,692 (46.7%) 414 (52.7%) 15,278 (46.6%) ** 2,017 (56.2%) 13,675 (45.6%) **
Framingham risk score2 9 (4 to 13) 11 (7 to 16) 8 (4 to 13) 11 (7 to 15) 8 (3 to 13)
Weight1 (kg) 76 (14) 77 (14) 76 (14) 77 (13) 76 (14)
BMI2 (kg/m2) 25.6 (23.5 to 28.1) 26.3 (24.3 to 29.0) 25.6 (23.4 to 28.1) ** 26.4 (24.2 to 29.0) 25.4 (23.3 to 27.8) **
Waist circumference1 (cm) 85 (11) 86 (11) 85 (11) * 86 (11) 85 (11) **
Hip circumference1 (cm) 102 (8) 103 (8) 102 (8) ** 103 (8) 101 (6) **
Waist/hip ratio1 0.84 (0.08) 0.84 (0.08) 0.84 (0.08) 0.83 (0.07) 0.84 (0.08) **
Systolic blood pressure2
(mmHg)
131 (120 to 144) 133 (122 to 146) 131 (120 to 144) * 133 (122 to 147) 131 (120 to 143) **
Diastolic blood pressure1
(mmHg)
79 (11) 80 (11) 79 (11) * 81 (11) 79 (11) **
Serum cholesterol1 (mmol/L) 5.8 (1.2) 6.0 (1.2) 5.8 (1.2) ** 6.1 (1.2) 5.8 (1.2) **
HDL cholesterol1 (mmol/L) 1.40 (0.39) 1.37 (0.39) 1.40 (0.39) 1.44 (0.40) 1.39 (0.38) **
Serum triglycerides2 (mmol/L) 1.40 (0.98 to 2.07) 1.51 (1.10 to 2.24) 1.40 (0.97 to 2.06) ** 1.46 (1.02 to 2.12) 1.37 (0.95 to 2.04) **
1Values are mean (standard deviation) or numbers (%), or 2median (interquartile range). Non-respondents were excluded. BMI, body mass index; CVD, cardiovascular
disease; HDL, high density lipoprotein; MI, myocardial infarction; OA, osteoarthritis; RA, rheumatoid arthritis. *P-value <0.05, **P-value <0.001, comparing individuals who
developed RA and did not develop RA, or comparing individuals who developed OA and did not develop OA. All blood samples were non-fasting.
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confirmed in the hospital registries for 216 participants
(27%) who had self-reported a new RA diagnosis in
HUNT3. The characteristics of these participants were
very similar to those reported for the entire group of in-
cident RA cases (data not shown). In the 216 cases with
a hospital diagnosis of RA, the diagnosis was found one
to two years following enrolment in HUNT2 for 14
cases (6.5%), after three years for 24 cases (11.1%), after
four years for 15 cases (6.9%), after five years for 28
cases (13.0%) and after six years for 22 cases (10.2%). For
the remaining 113 cases (52.3%), the times were distributed
from seven years onwards to the inclusion in HUNT3 with
numbers varying unsystematically from 15 to 24 cases
(6.9 to 11.1%) per year. Thus, there was no obvious pat-
tern regarding the number of years from HUNT2.In a separate alternative multivariate logistic regression
model containing gender, previous CV disease and the
Framingham risk score as covariates, the odds ratio for
developing RA in subjects with previous CV disease was
1.65 (1.21 to 2.24) (P <0.01). This model also suggested
the likelihood of developing RA was 6% greater with
each one unit increase in Framingham risk score (odds
ratio: 1.06, 95% CI: 1.05 to 1.08), P <0.001). The model
did not change with adjustment for BMI or daily use of
over-the-counter analgesics. In the model where the
Framingham risk score was substituted with the estimated
HeartScore, previous cardiovascular disease remained
significant (odds ratio: 1.70 (1.25 to 2.32), P <0.01). In the
100 participants where the HeartScore was calculated using
the PC-based calculator, the HeartScore (logarithmically
transformed) was highly correlated with the Framingham
Table 2 Effects of risk factors on incident RA and osteoarthritis, by multivariate logistic regression
Odds ratio 95% confidence interval P-value
I - Main model – Rheumatoid arthritis (n = 739 patients and 30,829 controls)1
Female gender 1.50 1.29 to 1.75 <0.01
Age2 1.03 1.02 to 1.04 <0.001
Current smoker 1.64 1.38 to 1.96 <0.001
Former smoker 1.32 1.10 to 1.59 <0.01
Hypertension 0.97 0.82 to 1.15 0.76
Diabetes 1.34 0.83 to 2.18 0.23
Body mass index2 1.04 1.02 to 1.06 <0.001
Previous CV disease 1.52 1.11 to 2.07 <0.01
II - Alternative models (sensitivity analyses) - Rheumatoid arthritis
A – After exclusion of patients with self-reported psoriasis (n = 573 patients and 30,829 controls)1
Previous CV disease3 1.70 1.23 to 2.36 0.001
B – Including patients with hospital diagnosis of RA (n = 201 patients and 30,829 controls)1
Previous CV disease3 1.90 1.10 to 3.27 0.02
C – Including patients with hospital diagnosis of RA after 1999 (n = 178 patients and 30,829 controls)1
Previous CV disease3 2.26 1.26 to 3.99
D – Including patients with hospital diagnosis of RA after 2001 (n = 138 patients and 30,829 controls)1
Previous CV disease3 2.51 1.33 to 4.73 <0.01
E – Including patients carrying the Shared Epitope (n = 313 patients and 30,829 controls)1
Previous CV disease3 1.76 1.13 to 2.74 0.01
F – Including patients carrying the Shared Epitope and excluding patients with self-reported psoriasis (n = 257 patients and 30,829 controls)1
Previous CV disease3 1.96 1.24 to 3.10 <0.01
III - Model for osteoarthritis (n = 3,364 patients and 24,631 controls)1
Female gender 2.36 2.15 to 2.56 <0.001
Age2 1.05 1.05 to 1.06 <0.001
Current smoker 1.42 1.30 to 1.56 <0.001
Former smoker 1.23 1.12 to 1.35 <0.001
Diabetes 0.90 0.66 to 1.22 0.49
Body mass index2 1.06 1.05 to 1.07 <0.001
Previous CV disease 1.04 0.86 to 1.27 0.66
1Cases with complete data.
2Continuous variable, Odds ratio per one unit change.
3Multivariate model including the same variables as the main model for RA. CV, cardiovascular; RA, rheumatoid arthritis.
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similar in patients (R = 0.89) and controls (R = 0.86).
At follow-up (2006 to 2008), 3,586 participants had
developed osteoarthritis, corresponding to an average
annual incidence of 1.05% in women and 0.64% in men,
respectively. These patients were older and the propor-
tion of smokers, former smokers and of those with
hypertension was higher than in the group that did not
develop osteoarthritis. Systolic and diastolic blood pres-
sure, BMI, hip and waist circumference, total cholesterol
and triglycerides were higher for incident cases of osteo-
arthritis, whereas HDL cholesterol was lower in incident
cases of osteoarthritis. Female gender, age and smokingwere associated with development of osteoarthritis, whereas
previous CV disease was not (Table 2 III).
Discussion
In the present large population-based health study we
found that participants who developed RA between
HUNT2 and HUNT3 had more CV disease and CV risk
factors prior to the onset of RA (at HUNT2) compared
to those without incident RA. A history of CV disease
was a significant risk factor for incident RA, as well as
the previously reported risk factors: female gender, in-
creasing age, increasing BMI and smoking [25]. The
finding of a positive association with the Framingham
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corporated into the score. The supplementary analysis
showed that the Framingham score was equivalent to the
estimated HeartScore in our population even though the
Framingham score was not developed from European sub-
jects. On the other hand, previous CV disease events did
not contribute to the risk of future osteoarthritis in our
study, indicating that the finding may be specific to RA.
Smoking was associated with incident osteoarthritis.
CV disease and incident RA
The design of our study has several strengths. Since the
data on the CV risk factors and events were collected at
HUNT2, recall bias at HUNT3 was greatly reduced com-
pared to a design where patients report on these factors
when receiving an RA diagnosis at a hospital-based clinic.
Furthermore, the observation time between HUNT2 and
HUNT3 was approximately 10 years. The importance of a
long observation time is underscored by the finding that
the odds ratio for the association of incident RA with pre-
vious CV disease increased when patients receiving a hos-
pital diagnosis of RA during the first years following
HUNT2 were excluded. It also seems biologically plausible
that longer exposure to increased inflammation due to CV
disease further increases the risk of incident RA. Further-
more, the statistical power is greatly improved in a
population-based cohort study due to the large number of
controls, and problems defining a relevant control group
as seen with case-control studies of RA are avoided.
The major limitation of our study is that data were
self-reported. Previous studies suggest that self-reported
CV diagnosis and risk factors, such as hypertension and
cigarette smoking, are reliable [26,27]. However, the high
incidence rate of self-reported RA in our study com-
pared, for example, to recent Swedish data based on in-
patient and non-primary outpatient care (0.056% in
women, 0.025% in men) [28], confirms that there prob-
ably were many false-positive RA diagnoses. This would
tend to decrease the power to detect true positive results
in our study, but not bias towards false-positive findings.
When including only cases identified in the hospital
registries, the incidence was close to the Swedish data.
Furthermore, the incidence of RA increases with obser-
vation time [29]. Therefore, different data may not be
directly comparable.
Epidemiological studies also carry a risk of reverse
causation, which could ensue if persons with undiag-
nosed RA in HUNT2 were erroneously included as inci-
dent cases of RA, because RA in itself increases the risk
of CV disease and events [10]. It seems unlikely that re-
verse causation could explain our findings, given that
the association with previous CV disease became stron-
ger when the cases with shortest duration between
HUNT2 and a hospital diagnosis of RA were removedfrom the analysis. Furthermore, we did not observe a
tendency for a higher number of cases with a hospital
diagnosis to occur during the earliest years following
HUNT2, which would have been expected with substan-
tial reverse causation.
While fatal CV events prior to the onset of RA also lim-
ited the participants in our study to survivors of those
events, this again would lead to under-estimation of the
impact of CV events on development of RA, or to restrict
the population at risk of RA to those ageing with CV risk
that was insufficient to lead to premature mortality. Auto-
antibodies were not measured and seropositive and sero-
negative cases of RA could not be distinguished, which
impacts on the generalizability of our results compared to
others, such as population-based cohorts where it was
concluded that ischemic heart disease was not increased
prior to RA onset [17]. There may also have been a selec-
tion bias regarding participation in HUNT, where sicker
people or those with a lower socioeconomic status are less
likely to join. These people have a higher risk both for CV
disease and for RA, which may have biased our findings.
The results from our various sensitivity analyses unani-
mously supported our main analysis. The overall conclu-
sion that a history of CV disease is associated with the risk
for incident RA therefore seems reliable. Although our
study may not be suitable to give an exact estimate of the
size of this increased risk, the main analysis giving an OR
of approximately 1.5 is probably conservative.
Risk factors for osteoarthritis
Our results identifying smoking as a risk factor for fu-
ture osteoarthritis contradict some previous studies,
which report an inverse association between smoking
and osteoarthritis [30]. However, the longitudinal pro-
spective Clearwater study designed to identify risk factors
for OA development, which included 2,505 participants,
did not support this inverse association with smoking for
any of four joint sites (knee, hand, foot or spine) [31].
In another prospective study of 1,003 participants from
the general population there was no association between
smoking and radiologically-confirmed OA at different
sites [32]. The current study may have shown an asso-
ciation with smoking because it is larger and included
a greater number of incident osteoarthritis diagnoses.
Nevertheless, since our study relies on self-report, replica-
tion in a cohort ascertained for radiographic osteoarthritis
and symptoms is needed. However, in support of the ac-
curacy of our case classification, we noted that higher BMI
increased the risk for osteoarthritis development, as previ-
ously described [33].
Inflammation as a link between CV disease and incident RA
From a biological perspective based on the current stud-
ies, we hypothesize that inflammation may contribute to
Figure 1 Proposed model for illustrating the relationship
among RA, CV disease, inflammation, atherosclerosis and
predisposing factors. CV, cardiovascular; RA, rheumatoid arthritis.
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ing the pre-clinical period in individuals exposed to
common RA and CV risk factors, just as this interaction
accelerates complication of RA by CV events after onset.
Inflammation is the most plausible link between previous
CV disease or BMI and increased risk for RA. It is well
established that the pathogenesis of CV disease, that is,
atherogenesis, includes chronic inflammation of the wall of
muscular arteries and that inflammation is increased during
acute coronary events, associated with unstable plaque and
thrombosis [16]. Furthermore, obesity induces chronic in-
flammation in adipose tissue, increasing pro-inflammatory
cytokines including interleukin-6 and tumour-necrosis
factor [34]. In addition, a pro-inflammatory state is present
before the clinical onset of RA. C reactive protein (CRP)
levels were found to be higher in individuals with pre-
clinical RA compared to a control group [35]. Serum cyto-
kines and chemokines were also elevated preceding the
onset of RA [36]. In at least some patients, periodontal in-
flammation may precede the onset of RA symptoms, also
associated with ACPA [37]. Respiratory inflammation has
also been described in ACPA positive individuals without
RA [38]. Autoantibodies may also increase the risk of im-
mune complex-mediated vascular inflammation [39]. Thus,
CV disease and CV risk factors increase the future risk of
RA development in the context of systemic inflammation
and autoantibody development [12]. Patients with seroposi-
tive RA are at greater risk of CV disease [6,40], and it is
possible that the RA genetic background is more permis-
sive to atherosclerosis when associated with the “lifestyle”
factors described here. In contrast to RA, in osteoarthritis
inflammation is local and low-grade rather than systemic,
and is not associated with autoantibodies.
Figure 1 proposes a model for the relationships among
RA, CV disease, inflammation and various predisposing
factors, based on the results from the present study, aswell as previous studies demonstrating an increased risk
of CV disease after diagnosis of RA. Given that our find-
ings were robust when adjusting for known risk factors
for RA, this hypothesis merits further investigation in
studies designed to clarify pathogenetic mechanisms,
which is not possible in an epidemiological study.
Conclusions
A history of previous CV disease was associated with in-
creased risk of incident RA but not osteoarthritis. A
probable explanation is that increased systemic inflam-
mation may contribute to the parallel development of
atherosclerosis and RA during the pre-clinical period in
individuals exposed to common RA and CV risk factors,
in a similar way that such interaction accelerates CV dis-
ease in patients with established RA. The association of
previous CV events with the development of RA at the
population level suggests presentation with CV events,
especially in middle-aged female smokers or first-degree
relatives of RA patients, should raise clinical suspicion
to capture cases of undiagnosed early RA. Because CV
risk factors are increased at the onset of RA, active car-
diovascular risk management is important from the time
of diagnosis.
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